Management of HIV/AIDS

1661:

that maintenance of HIV and AIDS should go beyond the suppression of viral load and the prevention of opportunistic infection. It proposes adding a 'fourth 90' addressing a new 'quality of life' target that would focus specifically on increasing the quality of life for those that are able to suppress their viral load to undetectable levels along with new metrics to track the progress toward that target. This study serves as an example of the shifting paradigm in the dynamics of the health care system from being heavily 'disease-oriented' to more 'human-centered'. Though questions remain of what exactly a more 'human-centered' method of treatment looks like in practice, it generally aims to ask what kind of support, other than medical support, PLHIV need to cope with and eliminate HIV-related stigmas. Campaigns and marketing aimed at educating the general public in order to reduce any misplaced fears of HIV contraction is one example. Also encouraged is the capacity-building and guided development of PLHIV into more leadership roles with the goal of having a greater representation of this population in decision making positions. Structural legal intervention has also been proposed, specifically referring to legal interventions to put in place protections against discrimination and improve access to employment opportunities. On the side of the practitioner, greater competence for the experience of people living with HIV is encouraged alongside the promotion of an environment of nonjudgment and confidentiality.

1657:

viral load. A 2009 meta-analysis studying the correlates of HIV-stigma found that individuals living with higher stigma burden were more likely to have poorer physical and mental health. Insufficient social support and delayed diagnosis due to decreased frequency of HIV testing and knowledge of risk reduction were cited as some of the reasons. People living with HIV (PLHIV) have lower health related quality of life (HRQoL) scores than do the general population. The stigma of having HIV is often compounded with the stigma of identifying with the LGBTQ community or the stigma of being an injecting drug user (IDU) even though heterosexual sexual transmission accounts for 85% of all HIV-1 infections worldwide. AIDS has been cited as the most heavily stigmatized medical condition among infectious diseases. Part of the consequence of this stigma toward PLHIV is the belief that they are seen as responsible for their status and less deserving of treatment.

1685:

management of HIV/AIDS. The lack of sufficient and constant income does limit the options for food, treatment, and medications. The same can be inferred for those who are among the oppressed groups in society who are marginalized and may be less inclined or encouraged to seek care and assistance. Endeavors to address food insecurity should be included in HIV treatment programs and may help improve health outcomes if it also focuses on health equity among the diagnosed as much as it focuses on medications. Access to consistently safe and nutritious foods is one of the most important facets in ensuring PLWHA are being provided the best possible care. By altering the narratives for HIV treatment so that more support can be garnered to reduce food insecurity and other health disparities mortality rates will decrease for people living with HIV/AIDS.

1681:

described as living with some level of poverty and food insecurity as reported by the NYC Department of Health on March 31, 2019. Having access to a consistent food supply that is safe and healthy is an important part in the treatment and management of HIV/AIDS. PLWHA are also greatly affected by food inequities and food deserts which causes them to be food insecure. Food insecurity, which can cause malnutrition, can also negatively impact HIV treatment and recovery from opportunistic infections. Similarly, PLWHA require additional calories and nutritionally support that require foods free from contamination to prevent further immunocompromising. Food insecurity can further exacerbate the progression of HIV/AIDS and can prevent PLWHA from consistently following their prescribed regimen, which will lead to poor outcomes.

994:

serodiscordant couples so long as "the partner living with HIV a durably suppressed viral load" include: Opposites Attract, PARTNER 1, PARTNER 2, (for male–male couples) and HPTN052 (for heterosexual couples). In these studies, couples where one partner was HIV-positive and one partner was HIV-negative were enrolled and regular HIV testing completed. In total from the four studies, 4097 couples were enrolled over four continents and 151,880 acts of condomless sex were reported, there were zero phylogenetically linked transmissions of HIV where the positive partner had an undetectable viral load. Following this the U=U consensus statement advocating the use of 'zero risk' was signed by hundreds of individuals and organisations including the US

436: 1053:

majority of increase in CD4 cell counts was in the first two years after starting ART with little increase afterwards. This study also found that patients who began ART at lower CD4 counts continued to have lower CD4 counts than those who started at higher CD4 counts. When viral suppression on ART is achieved but without a corresponding increase in CD4 counts it can be termed immunologic nonresponse or immunologic failure. While this is predictive of worse outcomes, there is no consensus on how to adjust therapy to immunologic failure and whether switching therapy is beneficial. DHHS guidelines do not recommend switching an otherwise suppressive regimen.

1059:(ILC) are another class of immune cell that is depleted during HIV infection. However, if ART is initiated before this depletion at around 7 days post infection, ILC levels can be maintained. While CD4 cell counts typically replenish after effective ART, ILCs depletion is irreversible with ART initiated after the depletion despite suppression of viremia. Since one of the roles of ILCs is to regulate the immune response to commensal bacteria and to maintain an effective gut barrier, it has been hypothesized that the irreversible depletion of ILCs plays a role in the weakened gut barrier of HIV patients, even after successful ART. 902:

older adult. There is data that older people with HIV have a blunted CD4 response to therapy but are more likely to achieve undetectable viral levels. However, not all studies have seen a difference in response to therapy. The guidelines do not have separate treatment recommendations for older adults, but it is important to take into account that older patients are more likely to be on multiple non-HIV medications and consider drug interactions with any potential HIV medications. There are also increased rates of HIV associated non-AIDS conditions (HANA) such as

72:, has written, "With collective and resolute action now and a steadfast commitment for years to come, an AIDS-free generation is indeed within reach." In the same paper, he noted that an estimated 700,000 lives were saved in 2010 alone by antiretroviral therapy. As another commentary noted, "Rather than dealing with acute and potentially life-threatening complications, clinicians are now confronted with managing a chronic disease that in the absence of a cure will persist for many decades." 104: 1218:

considered potentially infectious unless they are visibly bloody." Given the rare nature of these events, rigorous study of the protective abilities of antiretrovirals are limited but do suggest that taking antiretrovirals afterwards can prevent transmission. It is unknown if three medications are better than two. The sooner after exposure that ART is started the better, but after what period they become ineffective is unknown, with the

670:. In the US, 10.8% of one cohort of patients who had never been on ART before had at least one resistance mutation in 2005. Various surveys in different parts of the world have shown increasing or stable rates of baseline resistance as the era of effective HIV therapy continues. With baseline resistance testing, a combination of antiretrovirals that are likely to be effective can be customized for each patient. 1437:. In 2014 there were reports of the cure of HIV in two infants, presumably due to the fact that treatment was initiated within hours of infection, preventing HIV from establishing a deep reservoir. There is work being done to try to activate reservoir cells into replication so that the virus is forced out of latency and can be attacked by antiretrovirals and the host immune system. Targets include 11251: 1257:(IVF). Preferably this is done after the man has achieved an undetectable plasma viral load. In the past there have been cases of HIV transmission to an HIV-negative partner through processed artificial insemination, but a large modern series in which followed 741 couples where the man had a stable viral load and semen samples were tested for HIV-1, there were no cases of HIV transmission. 836:(an NNRTI) at the time of birth to prevent transmission. If this fails it can lead to NNRTI resistance. Also, a large study in Africa and India found that a PI based regimen was superior to an NNRTI based regimen in children less than 3 years who had never been exposed to NNRTIs in the past. Thus the WHO recommends PI based regimens for children less than 3. 1095:(or "structured treatment interruptions") are intentional discontinuations of antiretroviral drug treatment. As mentioned above, randomized controlled studies of structured treatment interruptions have shown higher rates of opportunistic infections, cancers, heart attacks and death in patients who took drug holidays. With the exception of 885:>100,000 copies/ml have a transmission risk of over 50%. The risk when viral loads are < 1000 copies/ml are less than 1%. ART for mothers both before and during delivery and to mothers and infants after delivery are recommended to substantially reduce the risk of transmission. The mode of delivery is also important, with a planned 866:

adolescents. They measured virologic suppression, death and adverse events. The authors found that there is no meaningful difference between abacavir-containing regimens and other NRTI-containing regimens. The evidence is of low to moderate quality and therefore it is likely that future research may change these findings.

535:(Vocabria), to be used together for the treatment of people with human immunodeficiency virus type 1 (HIV-1) infection. The two medicines are the first ARVs that come in a long-acting injectable formulation. This means that instead of daily pills, people receive intramuscular injections monthly or every two months. 5498:

with HIV had a durably suppressed viral load. Subsequently, the PARTNER and Opposites Attract studies confirmed these findings and extended them to male–male couples. ... The success of U=U as an HIV prevention method depends on achieving and maintaining an undetectable viral load by taking ART daily as prescribed.

1386:

majority of CD4+ cells capable of being infected. The analysis found that only patients where less than 40% of cells were infected had reduced viral load. The Gene therapy was not effective if the native CD4+ cells remained. This is the main limitation which must be overcome for this treatment to become effective.

1660:

A 2016 study sharing the WHO's definition of health critiques its 90-90-90 target goal, which is part of a larger strategy that aims to eliminate the AIDS epidemic as a public health threat by 2030, by arguing that it does not go far enough in ensuring the holistic health of PLHIV. The study suggests

1618:

of an mRNA vaccine showed that 97 percent of participants had the desired initial “priming” immune response of naive b cells. This is a positive result for developing the first shot in a vaccine sequence. Moderna is partnering with Scripps and the International AIDS Vaccine Initiative for a follow-up

1605:

In essence, the sequential immunization approach represents an attempt to mimic Env evolution that would occur with natural infection.... In contrast to traditional prime/boost strategies, in which the same immunogen is used repeatedly for vaccination, the sequential immunization approach relies on a

1355:

People living with HIV can expect to live a nearly normal life span if able to achieve durable viral suppression on combination antiretroviral therapy. However this requires lifelong medication and will still have higher rates of cardiovascular, kidney, liver and neurologic disease. This has prompted

1318:

were made available to ease the administration. Later, the term combination antiretroviral therapy (cART) gained favor with some physicians as a more accurate name, not conveying to patients any misguided idea of the nature of the therapy. Today multidrug, highly effective regimens are long since the

1071:

is sequenced which can be compared with databases of other HIV viral genotypes and resistance profiles to predict response to therapy. Resistance testing may improve virological outcomes in those who have treatment failures. However, there is lack of evidence of effectiveness of such testing in those

828:

HIV can be especially harmful to infants and children, with one study in Africa showing that 52% of untreated children born with HIV had died by age 2. By five years old, the risk of disease and death from HIV starts to approach that of young adults. The WHO recommends treating all children less than

815:

Since viral loads are usually very high during acute infection, this period carries an estimated 26 times higher risk of transmission. By treating acutely infected patients, it is presumed that it could have a significant impact on decreasing overall HIV transmission rates since lower viral loads are

593:

Furthermore, the PARTNER study, which ran from 2010 to 2014, enrolled 1166 serodiscordant couples (where one partner is HIV positive and the other is negative) in a study that found that the estimated rate of transmission through any condomless sex with the HIV-positive partner taking ART with an HIV

538:

The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines

515:

The timing of when to start therapy has continued to be a core controversy within the medical community, though recent studies have led to more clarity. The NA-ACCORD study observed patients who started antiretroviral therapy either at a CD4 count of less than 500 versus less than 350 and showed that

498:

In April 1995, Merck and the National Institute of Allergy and Infectious Diseases began recruiting patients for a trial examining the effects of a three drug combination of the protease inhibitor indinavir and two nucleoside analogs, illustrating the substantial benefit of combining two NRTIs with a

418:

In contrast, antiretroviral combination therapy defends against resistance by creating multiple obstacles to HIV replication. This keeps the number of viral copies low and reduces the possibility of a superior mutation. If a mutation that conveys resistance to one of the drugs arises, the other drugs

1656:

The preamble to the World Health Organization's Constitution defines health as "a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity." Those living with HIV today are met with other challenges that go beyond the singular goal of lowering their

1376:

cell surface receptor, which is needed for some variants of HIV to enter a cell. Bone marrow transplants carry their own significant risks including potential death and was only attempted because it was necessary to treat a blood cancer he had. Attempts to replicate this have not been successful and

966:

Cost: The WHO maintains a database of world ART costs which have dropped dramatically in recent years as more first line drugs have gone off-patent. A one pill, once a day combination therapy has been introduced in South Africa for as little as $ 10 per patient per month. One 2013 study estimated an

938:

in adults living with HIV, such as the effects of the virus on the brain, other infections or tumours, antiretroviral drugs and other medical treatment. Rates of major depression are higher in people living with HIV compared to the general population, and this may negatively influence antiretroviral

511:

became an advocate of this "hit hard, hit early" approach with aggressive treatment with multiple antiretrovirals early in the course of the infection. Later reviews in the late 90s and early 2000s noted that this approach of "hit hard, hit early" ran significant risks of increasing side effects and

154:

In rare cases, individuals may have a mutation in the CCR5 delta gene which results in a nonfunctional CCR5 co-receptor and in turn, a means of resistance or slow progression of the disease. However, as mentioned previously, this can be overcome if an HIV variant that targets CXCR4 becomes dominant.

5497:

NIAID Director Anthony S. Fauci, M.D., and colleagues summarize results from large clinical trials and cohort studies validating U=U. The landmark NIH-funded HPTN 052 clinical trial showed that no linked HIV transmissions occurred among HIV serodifferent heterosexual couples when the partner living

1415:

Alternative approaches aiming to mimic one's biological immunity to HIV through the absence or mutation of the CCR5 gene is being conducted in current research efforts. The efforts of which are done through the introduction of induced pluripotent stem cells that have been CCR5 disrupted through the

1307:. This concept of three-drug therapy was quickly incorporated into clinical practice and rapidly showed impressive benefit with a 60% to 80% decline in rates of AIDS, death, and hospitalization. It would also create a new period of optimism at the 11th International AIDS Conference that was held in 1292:

in 1987. The FDA bypassed stages of its review for safety and effectiveness in order to distribute this drug earlier. Subsequently, several more NRTIs were developed but even in combination were unable to suppress the virus for long periods of time and patients still inevitably died. To distinguish

1052:

CD4 cell counts are another key measure of immune status and ART effectiveness. CD4 counts should rise 50 to 100 cells per ml in the first year of therapy. There can be substantial fluctuation in CD4 counts of up to 25% based on the time of day or concomitant infections. In one long-term study, the

1021:

Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero.

901:

With improvements in HIV therapy, several studies now estimate that patients on treatment in high-income countries can expect a normal life expectancy. This means that a higher proportion of people living with HIV are now older and research is ongoing into the unique aspects of HIV infection in the

884:

The goals of treatment for pregnant women include the same benefits to the mother as in other infected adults as well as prevention of transmission to her child. The risk of transmission from mother to child is proportional to the plasma viral load of the mother. Untreated mothers with a viral load

1672:

The successful treatment and management of HIV/AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications, preventing opportunistic infection, and food access etc. Food insecurity is a condition in which households lack access to adequate food because of

1596:

Attempts to elicit an immune response that triggers broadly neutralizing antibodies (bnAbs) with a single vaccine dose have been unsuccessful. A multipart sequential mRNA vaccine regime, however, might guide the immune response in the right direction. The first shot triggers an immune response for

1217:

or contact with damaged skin, they are at risk for acquiring HIV. Pooled estimates give a risk of transmission with puncture exposures of 0.3% and mucous membrane exposures 0.63%. United States guidelines state that "feces, nasal secretions, saliva, sputum, sweat, tears, urine, and vomitus are not

1079:

test of a patient's virus against a range of drug concentrations can be performed, but is expensive and can take several weeks, so genotypes are generally preferred. Using information from a genotype or phenotype, a regimen of three drugs from at least two classes is constructed that will have the

947:

researchers assessed whether giving antidepressants to adults living with both HIV and depression may improve depression. Ten trials, of which eight were done in high-income countries, with 709 participants were included. Results indicated that antidepressants may be better in improving depression

609:

There are several treatment guidelines for HIV-1 infected adults in the developed world (that is, those countries with access to all or most therapies and laboratory tests). In the United States there are both the International AIDS Society-USA (IAS-USA) (a 501(c)(3) not-for-profit organization in

547:

A separate argument for starting antiretroviral therapy that has gained more prominence is its effect on HIV transmission. ART reduces the amount of virus in the blood and genital secretions. This has been shown to lead to dramatically reduced transmission of HIV when one partner with a suppressed

516:

patients who started ART at lower CD4 counts had a 69% increase in the risk of death. In 2015 the START and TEMPRANO studies both showed that patients lived longer if they started antiretrovirals at the time of their diagnosis, rather than waiting for their CD4 counts to drop to a specified level.

177:

which inhibit reverse transcription. HIV is an RNA virus, so it can not be integrated into the DNA in the nucleus of the human cell unless it is first "reverse" transcribed into DNA. Since the conversion of RNA to DNA is not naturally done in the mammalian cell, it is performed by a viral protein,

1680:

in the United States of America, which significantly affects minority groups, people living at or below the poverty line, and those who are living with one or more morbidity. As of December 31, 2017, there were approximately 126,742 people living with HIV/AIDS (PLWHA) in NYC, of whom 87.6% can be

1643:

harmed consumers by implying unproven benefits and failing to disclose important information about the drugs. Overall, some drug companies chose not to present their drugs in a realistic way, which consequently harmed the general public's ideas, suggesting that HIV would not affect you as much as

988:

Research has shown that people with an undetectable viral load are unable to transmit the virus through condomless sex with a partner of either gender. The 'Swiss Statement' of 2008 described the chance of transmission as 'very low' or 'negligible,' but multiple studies have since shown that this

984:

Suppressing the viral load to undetectable levels (<50 copies per ml) is the primary goal of ART. This should happen by 24 weeks after starting combination therapy. Viral load monitoring is the most important predictor of response to treatment with ART. Lack of viral load suppression on ART is

807:

In the first six months after infection HIV viral loads tend to be elevated and people are more often symptomatic than in later latent phases of HIV disease. There may be special benefits to starting antiretroviral therapy early during this acute phase, including lowering the viral "set-point" or

585:

In July 2016 a consensus document was created by the Prevention Access Campaign which has been endorsed by over 400 organisations in 58 countries. The consensus document states that the risk of HIV transmission from a person living with HIV who has been undetectable for a minimum of six months is

480:

immune cells, but does not make a difference in terms of death and incidence of other infections. Furthermore, there is probably an increase in side-effects with interleukin 2. The findings of this review do not support the use of interleukin 2 as an add-on treatment to antiretroviral therapy for

1684:

It is imperative that these food insecurity among PLWHA are addressed and rectified to reduce this health inequity. It is important to recognized that socioeconomic status, access to medical care, geographic location, public policy, race and ethnicity all play a pivotal role in the treatment and

661:

Baseline resistance is the presence of resistance mutations in patients who have never been treated before for HIV. In countries with a high rate of baseline resistance, resistance testing is recommended before starting treatment; or, if the initiation of treatment is urgent, then a "best guess"

494:

Antiretroviral drug treatment guidelines have changed over time. Before 1987, no antiretroviral drugs were available and treatment consisted of treating complications from opportunistic infections and malignancies. After antiretroviral medications were introduced, most clinicians agreed that HIV

1385:

has been used in a Phase I trial of 12 humans and led to an increase in CD4 count and decrease in their viral load while off antiretroviral treatment. Attempt to reproduce this failed in 2016. Analysis of the failure showed that gene therapy only successfully treats 11–28% of cells, leaving the

601:

allows the drug resistant strains to become dominant. This in turn makes it harder to treat the infected individual as well as anyone else they infect. One trial showed higher rates of opportunistic infections, cancers, heart attacks and death in patients who periodically interrupted their ART.

600:

There is a consensus among experts that, once initiated, antiretroviral therapy should never be stopped. This is because the selection pressure of incomplete suppression of viral replication in the presence of drug therapy causes the more drug sensitive strains to be selectively inhibited. This

304:

block the viral protease enzyme necessary to produce mature virions upon budding from the host membrane. Particularly, these drugs prevent the cleavage of gag and gag/pol precursor proteins. Virus particles produced in the presence of protease inhibitors are defective and mostly non-infectious.

155:

To prevent fusion of the virus with the host membrane, enfuvirtide can be used. Enfuvirtide is a peptide drug that must be injected and acts by interacting with the N-terminal heptad repeat of gp41 of HIV to form an inactive hetero six-helix bundle, therefore preventing infection of host cells.

993:

are their 'U=U' or 'Undetectable=Untransmittable' public information strategy, an approach that has gained widespread support amongst HIV/AIDS-related medical, charitable, and research organisations. The studies demonstrating that U=U is an effective strategy for preventing HIV transmission in

865:

assessed the effects and safety of abacavir-containing regimens as first-line therapy for children between 1 month and 18 years of age when compared to regimens with other NRTIs. This review included two trials and two observational studies with almost eleven thousand HIV infected children and

563:

heterosexual couples in nine countries were planned to be followed for at least 10 years, with both groups receiving education on preventing HIV transmission and condoms, but only one group getting ART. The study was stopped early (after 1.7 years) for ethical reasons when it became clear that

643:

Patients starting ART should be willing and able to commit to treatment and understand the benefits and risks of therapy and the importance of adherence. Patients may choose to postpone therapy, and providers, on a case-by-case basis, may elect to defer therapy on the basis of clinical and/or

115:

life-cycle that the drug inhibits. Typical combinations include two nucleoside reverse-transcriptase inhibitors (NRTI) as a "backbone" along with one non-nucleoside reverse-transcriptase inhibitor (NNRTI), protease inhibitor (PI) or integrase inhibitors (also known as integrase nuclear strand

94:

The WHO has defined health as more than the absence of disease. For this reason, many researchers have dedicated their work to better understanding the effects of HIV-related stigma, the barriers it creates for treatment interventions, and the ways in which those barriers can be circumvented.

892:

HIV can also be detected in breast milk of infected mothers and transmitted through breast feeding. The WHO balances the low risk of transmission through breast feeding from women who are on ART with the benefits of breastfeeding against diarrhea, pneumonia and malnutrition. It also strongly

431:

Because of HIV's tendency to mutate, when patients who have started an antiretrovial regimen fail to take it regularly, resistance can develop. On the other hand, patients who take their medications regularly can stay on one regimen without developing resistance. This greatly increases life

1198:

Integrase inhibitors (INSTIs) are among the best tolerated of the antiretrovirals with excellent short and medium term outcomes. Given their relatively new development there is less long term safety data. They are associated with an increase in creatinine kinase levels and rarely myopathy.

1554:

SARS-CoV-2 and HIV-1 have similarities—notably both are RNA viruses—but there are important differences. As a retrovirus, HIV-1 can insert a copy of its RNA genome into the host's DNA, making total eradication more difficult. The virus is also highly mutable making it a challenge for the

812:). The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed the time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped. 512:

development of multidrug resistance, and this approach was largely abandoned. The only consensus was on treating patients with advanced immunosuppression (CD4 counts less than 350/μL). Treatment with antiretrovirals was expensive at the time, ranging from $ 10,000 to $ 15,000 a year.

1412:", was confirmed to be in complete remission of HIV. Like the Berlin Patient, the London Patient received a bone marrow transplant from a donor who has the same CCR5 mutation. He has been off antiviral drugs since September 2017, indicating the Berlin Patient was not a "one-off". 1577:—mature B cells not yet exposed to any antigen and are the progenitors of bnAbs—are rare. Further, the mutation events needed to turn these B cells into bnAbs are also rare. Because of this, there is a growing consensus that an effective HIV vaccine will need to create not only 1593:, where the virus copies its genetic material into the host's genome, is not present. Another advantage when compared to traditional vaccines is the speed of development. mRNA vaccines take months not years, which means a multipart sequential vaccine regime is possible. 662:

treatment regimen should be started, which is then modified on the basis of resistance testing. In the UK, there is 11.8% medium to high-level resistance at baseline to the combination of efavirenz + zidovudine + lamivudine, and 6.4% medium to high level resistance to

423:

is to use combinations of antiretroviral drugs. Combinations usually consist of three drugs from at least two different classes. This three drug combination is commonly known as a triple cocktail. Combinations of antiretrovirals are subject to positive and negative

5843:

Gazzola L, Tincati C, Bellistrì GM, Monforte A, Marchetti G (February 2009). "The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options".

419:

continue to suppress reproduction of that mutation. With rare exceptions, no individual antiretroviral drug has been demonstrated to suppress an HIV infection for long; these agents must be taken in combinations in order to have a lasting effect. As a result, the

1644:

suggested. This led to people not wanting to get tested, for fear of being HIV positive, because at the time (in the 1980s and 1990s particularly), having contracted HIV was seen as a death sentence, as there was no known cure. An example of such a case is

276:

became the first to receive FDA approval in October 2007. Raltegravir has two metal binding groups that compete for substrate with two Mg ions at the metal binding site of integrase. As of early 2022, four other clinically approved integrase inhibitors are

1227:(an INSTI). The rationale for this regimen is that it is "tolerable, potent, and conveniently administered, and it has been associated with minimal drug interactions." People who are exposed to HIV should have follow up HIV testing at 6, 12, and 24 weeks. 1012:

as "impossible to overstate", while lead author Alison Rodger declared that the message that "undetectable viral load makes HIV untransmittable ... can help end the HIV pandemic by preventing HIV transmission." The authors summarised their findings in

388:

superiority to their parent and can enable them to slip past defenses such as the human immune system and antiretroviral drugs. The more active copies of the virus, the greater the possibility that one resistant to antiretroviral drugs will be made.

1146:

Mitochondrial Haplogroups(mtDNA), non pathologic mutations inherited from the maternal line, have been linked to the efficacy of CD4+ count following ART. Idiosyncratic toxicity with mtDNA haplogroup is also well studied (Boeisteril et al., 2007).

182:, which makes it a selective target for inhibition. NRTIs are chain terminators. Once NRTIs are incorporated into the DNA chain, their lack of a 3' OH group prevents the subsequent incorporation of other nucleosides. Both NRTIs and NtRTIs act as 467:

Although antiretroviral therapy has helped to improve the quality of life of people living with HIV, there is still a need to explore other ways to further address the disease burden. One such potential strategy that was investigated was to add

8639:"A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health" 5510:

Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. (August 2018). "Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study".

829:

5 years old, and starting all children older than 5 with stage 3 or 4 disease or CD4 <500 cells/ml. DHHS guidelines are more complicated but recommend starting all children less than 12 months old and children of any age who have symptoms.

629:

The guidelines use new criteria to consider starting HAART, as described below. However, there remain a range of views on this subject and the decision of whether to commence treatment ultimately rests with the patient and his or her doctor.

4407:

Musiime V, Ssali F, Kayiwa J, Namala W, Kizito H, Kityo C, et al. (October 2009). "Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine".

5758:

Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA (January 1994). "Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring".

1588:

mRNA vaccines have advantages over traditional vaccines which may help deal with some of the challenges presented by the HIV virus. The mRNA in the vaccine only codes for the protein spike, not the whole virus, so the possibility of

1377:

given the risks, expense and rarity of CCR5 negative donors, bone marrow transplant is not seen as a mainstream option. It has inspired research into other methods to try to block CCR5 expression through gene therapy. A procedure

5561:"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study" 1634:

rather than typical people with HIV/AIDS. Usually, these people will present with debilitating conditions or illnesses as a result of HIV/AIDS. In contrast, by featuring people in unrealistically strenuous activities, such as

1709: 6674:

Ippolito G, Puro V, De Carli G (June 1993). "The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection".

233:. NNRTIs affect the handling of substrate (nucleotides) by reverse transcriptase by binding near the active site. NNRTIs can be further classified into 1st generation and 2nd generation NNRTIs. 1st generation NNRTIs include 3350:

Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. (January 2000). "Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study".

7121:"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team" 9210: 1222:

Guidelines recommending starting prophylaxis up to a week after exposure. They also recommend treating for a duration of four weeks based on animal studies. Their recommended regimen is emtricitabine + tenofovir +

590:, stated in July 2017 that 'there should be no doubt about the clear and simple message that a person with sustained, undetectable levels of HIV virus in their blood cannot transmit HIV to their sexual partners.' 1432:

state, while antiretrovirals only attack actively replicating HIV. The cells in which HIV lies dormant are called the viral reservoir, and one of the main sources is thought to be central memory and transitional

5287:

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. (July 2012). "Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel".

10648: 1704: 568:, consistent with a 96% reduction in risk of transmission while on ART. The single transmission in the experimental group occurred early after starting ART before viral load was likely to be suppressed. 519:

Other arguments for starting therapy earlier are that people who start therapy later have been shown to have less recovery of their immune systems, and higher CD4 counts are associated with less cancer.

4105:"Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals" 3890:"Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy" 1639:; this proved to be offensive and insensitive to the suffering of people who are HIV positive. The US FDA reprimanded multiple pharmaceutical manufacturers for publishing such adverts in 2001, as the 5104: 1397:

Annemarie Wensing of the University Medical Center Utrecht announced this development during her presentation at the 2016 "Towards an HIV Cure" symposium. However, these two patients are still on

4336:

Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F (8 October 2004). "Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis".

572:(PrEP) provides HIV-negative individuals with medication—in conjunction with safer-sex education and regular HIV/STI screenings—in order to reduce the risk of acquiring HIV. In 2011, the journal 392:

When antiretroviral drugs are used improperly, multi-drug resistant strains can become the dominant genotypes very rapidly. In the era before multiple drug classes were available (pre-1997), the

597:

In summary, as the WHO HIV treatment guidelines state, "The ARV regimens now available, even in the poorest countries, are safer, simpler, more effective and more affordable than ever before."

1461:

to restore CD4+ cell counts as well as therapeutic vaccines to prime immune responses. One such candidate vaccine is Tat Oyi, developed by Biosantech. This vaccine is based on the HIV protein

1339:

alone now covers their meaning. Thus as "all computers are digital now", so "all ART is combination ART now." However, the names HAART and cART, reinforced by thousands of earlier mentions in

1241:

Women with HIV have been shown to have decreased fertility which can affect available reproductive options. In cases where the woman is HIV negative and the man is HIV positive, the primary

820:). However an overall benefit has not been proven and has to be balanced with the risks of HIV treatment. Therapy during acute infection carries a grade BII recommendation from the US DHHS. 10622: 9205: 7483:"Allogeneic Stem Cell Transplantation in HIV-1 infected individuals; the EpiStem Consortium [Conference Reports for NATAP] [IAS Durban HIV cure Symposium July 16–17 2016]" 778:

enzymes and "boost" the levels of other protease inhibitors, rather than for its direct antiviral effect. This boosting effect allows them to be taken less frequently throughout the day.

10540: 1347:, also remain in use. In 1997, the new number of new HIV/AIDS cases in the United States would see its first significant decline at 47%, with credit going to the effectiveness of HAART. 1573:, or bnAbs, have been shown to attach to the Env spike protein envelope regardless of the specific HIV mutations. This bodes well for vaccine development. Complicating matters, though, 4494:"Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis" 2585:"Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain" 1428:

The main obstacle to complete elimination of HIV infection by conventional antiretroviral therapy is that HIV is able to integrate itself into the DNA of host cells and rest in a

4642:"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States" 1457:

Even with all latent virus deactivated, it is thought that a vigorous immune response will need to be induced to clear all the remaining infected cells. Strategies include using

2018: 345:, was halted in 2010. Resistance to some protease inhibitors is high. Second generation drugs have been developed that are effective against otherwise resistant HIV variants. 9517: 4013:"A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City" 7387:

HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene Aridaman Pandit & Rob J. de Boer. Scientific Reports volume 5, Article number: 18088 (2016)

6717:"Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis" 2484:

Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (March 1996). "HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time".

990: 967:

overall cost savings to ART therapy in South Africa given reduced transmission. In the United States, new on-patent regimens can cost up to $ 28,500 per patient, per year.

10642: 6772:"A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group" 10832: 9481: 357:

can be as short as about 1.5 days from viral entry into a cell, through replication, assembly, and release of additional viruses, to infection of other cells. HIV lacks

3572:: When the statement and list of endorsements was retrieved, it had last been updated on 23 August 2018 and included "over 850 organizations from nearly 100 countries." 1664:

Psychosocial group interventions such as psychotherapy, relaxation, group support, and education may have some beneficial effects on depression in HIV positive people.

10837: 3121:

Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. (August 2015). "A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa".

586:

negligible to non-existent, with negligible being defined as "so small or unimportant to be not worth considering". The Chair of the British HIV Association (BHIVA),

7449: 1527:. This was a key breakthrough in optimizing the efficiency and efficacy of in vivo delivery. When the vaccine is injected, the mRNA enters cells and joins up with a 111:

There are six classes of drugs, which are usually used in combination, to treat HIV infection. Antiretroviral (ARV) drugs are broadly classified by the phase of the

10783: 9200: 4159: 4060:

Pérez L, Kourí V, Alemán Y, Abrahantes Y, Correa C, Aragonés C, et al. (June 2013). "Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba".

989:

mode of sexual transmission is impossible where the HIV-positive person has a consistently undetectable viral load. This discovery has led to the formation of the

7508: 985:

termed virologic failure. Levels higher than 200 copies per ml is considered virologic failure, and should prompt further testing for potential viral resistance.

9572: 3589:"Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy" 8779:"Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population" 1673:

limited money or other resources. Food insecurity is a global issue that has affected billions of people yearly, including those living in developed countries.

87:. Because of the complexity of selecting and following a regimen, the potential for side effects, and the importance of taking medications regularly to prevent 10255: 10168: 1067:

In patients who have persistently detectable viral loads while taking ART, tests can be done to investigate whether there is drug resistance. Most commonly a

11222: 8652:

Kallen A, Woloshin S, Shu J, Juhl E, Schwartz L (1 October 2007). "Direct-to-consumer advertisements for HIV antiretroviral medications: a progress report".

5485: 2639: 1031: 698: 69: 3931:"National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011" 1597:

the correct naive B cells. Later vaccinations encourage the development of these cells further, eventually turning them into memory b cells, and later into

10419: 1699: 1293:

from this early antiretroviral therapy (ART), the term highly active antiretroviral therapy (HAART) was introduced. In 1996 two sequential publications in

455:

have been developed. This greatly increases the ease with which they can be taken, which in turn increases the consistency with which medication is taken (

10163: 9217: 5112: 7219: 5731: 8911:

Wolfe D, Carrieri MP, Shepard D (July 2010). "Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward".

4545:"Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group" 2452: 1551:. Memory B cells then produce the antibodies, hopefully destroying the virus before it can bind to another cell and repeat the HIV life cycle. 91:, such organizations emphasize the importance of involving patients in therapy choices and recommend analyzing the risks and the potential benefits. 1022:

Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV.

832:

As for which antiretrovirals to use, this is complicated by the fact that many children who are born to mothers with HIV are given a single dose of

10789: 9678: 6301:"T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384" 5987:"Progressive proximal-to-distal reduction in expression of the tight junction complex in colonic epithelium of virally-suppressed HIV+ individuals" 1480:. Research into a vaccine for HIV has been ongoing for decades with no lasting success for preventing infection. The rapid development, though, of 1393:", two additional patients with both HIV infection and cancer were reported to have no traceable HIV virus after successful stem cell transplants. 1299:

by Hammer and colleagues and Gulick and colleagues illustrated the substantial benefit of combining two NRTIs with a new class of antiretrovirals,

8641:. ModernaTX, Inc., The University of Texas at San Antonio, George Washington University, Fred Hutchinson Cancer Research Center, Emory University. 4668:"Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease" 10847: 10767: 9151: 5184: 3271: 1492: 970:

Public health: Individuals who fail to use antiretrovirals as directed can develop multi-drug resistant strains which can be passed onto others.

10852: 6252:"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors" 1368:" has been potentially cured of HIV infection and has been off of treatment since 2006 with no detectable virus. This was achieved through two 452: 7565:"CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus" 4103:

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N, et al. (Cochrane Infectious Diseases Group) (December 2016).

3291:

Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

564:

antiviral treatment provided significant protection. Of the 28 couples where cross-infection had occurred, all but one had taken place in the

10800: 10201: 9552: 2863:"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy" 2735:

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (August 2007). "Fixed-dose combinations improve medication compliance: a meta-analysis".

1531:. The ribosome then translates the mRNA instructions into the spike protein. The immune system detects the presence of the spike protein and 960:

Intolerance: The drugs can have serious side-effects which can lead to harm as well as keep patients from taking their medications regularly.

6411:"The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy" 6360:"European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy" 10822: 10806: 7703: 7536: 5447: 2703: 1559:

to develop a response. As a chronic infection, HIV-1 and the adaptive immune system undergo reciprocal selective pressures leading to the

143:, a co-receptor located on human helper T-cells. Caution should be used when administering this drug, however, due to a possible shift in 11175: 11170: 9424: 9243: 9193: 9141: 1040: 2417:

Wensing AM, van Maarseveen NM, Nijhuis M (January 2010). "Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance".

376:. Its short life-cycle and high error rate cause the virus to mutate very rapidly, resulting in a high genetic variability. Most of the 10817: 9537: 7424: 1285: 995: 495:

positive patients with low CD4 counts should be treated, but no consensus formed as to whether to treat patients with high CD4 counts.

5477: 2236:

Bai Y, Xue H, Wang K, Cai L, Qiu J, Bi S, et al. (February 2013). "Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket".

10827: 6358:

Guzmán-Fulgencio M, Berenguer J, Micheloud D, Fernández-Rodríguez A, García-Álvarez M, Jiménez-Sousa MA, et al. (October 2013).

893:

recommends that breastfeeding infants receive prophylactic ART. In the US, the DHHS recommends against women with HIV breastfeeding.

11094: 9351: 5613:

Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: The PARTNER2 Study extended results in gay men

6449:

Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

2625: 2201:

Lieberman-Blum SS, Fung HB, Bandres JC (July 2008). "Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection".

10738: 7774:"Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection" 1315: 1080:

highest probability of suppressing the virus. If a regimen cannot be constructed from recommended first line agents it is termed

611: 448: 76: 7015: 3972:"Surveillance of transmitted HIV drug resistance in antiretroviral-naive patients aged less than 25 years, in Bangkok, Thailand" 2109:

Logie C, Gadalla TM (June 2009). "Meta-analysis of health and demographic correlates of stigma towards people living with HIV".

1143:. First-line NRTIs such as lamivudine/emtrictabine, tenofovir, and abacavir are less likely to cause mitochondrial dysfunction. 9263: 9093: 8744: 6972:

Coutsoudis A, Kwaan L, Thomson M (October 2010). "Prevention of vertical transmission of HIV-1 in resource-limited settings".

4717:"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy" 4189:"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro" 2660:

Bangsberg DR, Kroetz DL, Deeks SG (May 2007). "Adherence-resistance relationships to combination HIV antiretroviral therapy".

127:(or fusion inhibitors) interfere with binding, fusion and entry of HIV-1 to the host cell by blocking one of several targets. 11193: 11084: 9512: 7052: 4171: 3652: 2343: 1615: 1570: 879: 808:

baseline viral load, reduce the mutation rate of the virus, and reduce the size of the viral reservoir (See section below on

60:

Treatment has been so successful that in many parts of the world, HIV has become a chronic condition in which progression to

2992: 9943: 1178:, a strong inhibitor of cytochrome P450 enzymes, leading to numerous drug-drug interactions. They are also associated with 7931: 7456: 6504:"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability" 3557:"Consensus statement: Risk of Sexual Transmission of HIV from a Person Living with HIV who has an Undetectable Viral Load" 1008:

medical journal. The importance of the final results of the PARTNER 2 study were described by the medical director of the

10842: 10179: 9631: 7076:

Moore RD, Chaisson RE (April 1996). "Natural history of opportunistic disease in an HIV-infected urban clinical cohort".

3168:"Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment" 1417: 1295: 1219: 7606:"CRISPR-Cas9: how research on a bacterial RNA-guided mechanism opened new perspectives in biotechnology and biomedicine" 3775:"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel" 1401:, which is not the case for the Berlin patient. Therefore, it is not known whether or not the two patients are cured of 10857: 10068: 9308: 1959: 637:

Antiretroviral therapy (ART) is recommended for all HIV-infected individuals to reduce the risk of disease progression.

7455:. Durban International Convention Centre (ICC), Durban, South Africa: AIDS Society (IAS). 21 June 2016. Archived from 6639:

Bell DM (May 1997). "Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview".

10413: 10194: 9491: 9381: 7199:

When Did HAART Become ART? Change Is About More Than Just Semantics [reviewed by a board-certified physician]

3004: 2380: 948:

compared to placebo, but the quality of the evidence is low and future research is likely to impact on the findings.

764: 683: 301: 8563: 6904:

Centers for Disease Control (CDC) (April 1990). "HIV-1 infection and artificial insemination with processed semen".

11210: 10867: 10751: 9238: 7963:"Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine" 9003: 5881:"Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression" 5056: 11281: 10877: 10862: 10525: 10513: 6459:

Boelsterli UA, Lim PL (April 2007). "Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?".

1441:(HDAC) which represses transcription and if inhibited can lead to increased cell activation. The HDAC inhibitors 539:

called non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors (INIs).

393: 272:

of viral DNA into the DNA of the infected cell. There are several integrase inhibitors under clinical trial, and

218: 163: 6108:"HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort" 1523:

or messenger RNA, contains the instructions for how to make the spike protein. The mRNA is put into lipid-based

10757: 9971: 9233: 1627: 6057:

Aves T, Tambe J, Siemieniuk RA, Mbuagbaw L, et al. (Cochrane Infectious Diseases Group) (November 2018).

4666:

Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, Mbori-Ngacha DA, et al. (March 2003).

1818:(February 2019). "HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable". 11271: 10033: 9547: 9527: 9258: 9146: 7197: 5481: 1035: 88: 57:

same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

4382: 2041:

Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo Valero J, et al. (June 2016).

1213:

When people are exposed to HIV-positive infectious bodily fluids either through skin puncture, contact with

10187: 10146: 9419: 9407: 9288: 9248: 2635: 1289: 1242: 1179: 527:(EMA) has recommended the granting of marketing authorizations for two new antiretroviral (ARV) medicines, 473: 8954:

van der Heijden I, Abrahams N, Sinclair D, et al. (Cochrane Infectious Diseases Group) (March 2017).

8564:"First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research" 3929:

Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, et al. (November 2013).

2462: 164:

Nucleoside reverse-transcriptase inhibitors (NRTI) and nucleotide reverse-transcriptase inhibitors (NtRTI)

10962: 9918: 9614: 9542: 9471: 9429: 9173: 9131: 7032: 2583:

Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, et al. (November 1996).

1208: 1099:(PEP), treatment guidelines do not call for the interruption of drug therapy once it has been initiated. 435: 7171: 5796:"Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection" 3644:

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection<

963:

Resistance: Not taking medication consistently can lead to low blood levels that foster drug resistance.

107:

Schematic description of the mechanism of the four classes of available antiretroviral drugs against HIV

11241: 9608: 9532: 9522: 9253: 9086: 8216: 6770:

Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. (November 1997).

3841:"Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study" 1630:

and other advertisements for HIV drugs in the past were criticized for their use of healthy, glamorous

1524: 1519:

binds to the host cell's receptor and is what gains the virus entry into the cell. With mRNA vaccines,

749: 226: 5192: 3303:"Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding" 1465:. Animal models have shown the generation of neutralizing antibodies and lower levels of HIV viremia. 61: 10082: 10050: 10038: 9991: 9567: 5009:"Antiretroviral medication adherence and the development of class-specific antiretroviral resistance" 3276: 1250: 1096: 956:

There are several concerns about antiretroviral regimens that should be addressed before initiating:

782:

is used with elvitegravir for a similar effect but does not have any direct antiviral effect itself.

618: 524: 80: 8823:"Health-related quality of life assessment after antiretroviral therapy: a review of the literature" 7653:

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. (August 2009).

6813:"Decreased fertility among HIV-1-infected women attending antenatal clinics in three African cities" 5928:

Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA, Kunisawa J, et al. (June 2012).

5879:

Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al. (February 2016).

4641: 3888:

Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. (February 2005).

3365: 3301:

Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, et al. (February 2007).

1319:

default in ART, which is why they are increasingly called simply ART instead of HAART or cART. This

694:("base"). Initial regimens use "first-line" drugs with a high efficacy and low side-effect profile. 11034: 10944: 10925: 10812: 10773: 9923: 9773: 9646: 9334: 9293: 8241:

Fischer W, Giorgi EE, Chakraborty S, Nguyen K, Bhattacharya T, Theiler J, et al. (July 2021).

7119:

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. (September 1997).

6715:

Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. (September 2013).

4443:

Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. (June 2012).

3404:

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. (August 2011).

2506: 2154:"Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection" 1543:. Should the actual virus later enter the system, the external spike protein will be recognized by 1477: 701:

preferred initial regimens for adults and adolescents in the United States, as of April 2015, are:

579: 569: 415:

were used serially or in combination leading to the development of multi-drug resistant mutations.

50: 9024:

Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, et al. (June 2005).

4589:"Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy" 3217:"HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies" 652:

Antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count

337:

have a similar effect by binding to gag, but development of two experimental drugs in this class,

11198: 10794: 10141: 10013: 9888: 9806: 9708: 9273: 9268: 7961:

Watkins JD, Lancelot S, Campbell GR, Esquieu D, de Mareuil J, Opi S, et al. (January 2006).

3672: 1473: 1261: 999: 944: 476:

that were conducted across six countries. The researchers found that interleukin 2 increases the

8956:"Psychosocial group interventions to improve psychological well-being in adults living with HIV" 7655:"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation" 5439: 4854:

Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, et al. (October 2010).

3671:

El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. (November 2006).

1044:, that U=U is an effective HIV prevention method when an undetectable viral load is maintained. 774:

In the case of the protease inhibitor based regimens, ritonavir is used at low doses to inhibit

384:(often lacking the ability to reproduce at all) or convey no advantage, but some of them have a 264:(also known as integrase nuclear strand transfer inhibitors or INSTIs) inhibit the viral enzyme 10872: 9853: 9826: 9816: 9738: 9723: 9621: 9441: 9371: 9178: 7831:

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. (July 2012).

5443: 5134:

Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. (October 2013).

3360: 2861:

Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. (September 1997).

2713: 2501: 1640: 1582: 1560: 1556: 1405:. The cure might be confirmed if the therapy were to be stopped and no viral rebound occurred. 1369: 1254: 1009: 640:

ART also is recommended for HIV-infected individuals for the prevention of transmission of HIV.

447:

In 2000 drug companies have worked together to combine these complex regimens into single-pill

358: 269: 10980: 7509:"A decade after the first person was cured of HIV, a second patient is in long-term remission" 6299:

Hulgan T, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, et al. (27 August 2012).

5930:"Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria" 5638:, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. (September 2016). 3642: 3587:

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. (July 2016).

3023:

Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. (April 2009).

11276: 11069: 10882: 10762: 10632: 10231: 10136: 10090: 10028: 10018: 9928: 9863: 9434: 9402: 9339: 9163: 9079: 8873:

Mak WW, Poon CY, Pun LY, Cheung SF (July 2007). "Meta-analysis of stigma and mental health".

6811:

Glynn JR, Buvé A, Caraël M, Kahindo M, Macauley IB, Musonda RM, et al. (December 2000).

5690: 3724:

Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. (September 2007).

3455:"Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?" 3166:

Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. (March 2009).

2996: 1714: 1590: 1132: 923: 456: 373: 230: 222: 183: 179: 7772:

Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. (February 2010).

7089: 771:

Both efavirenz and nevirapine showed similar benefits when combined with NRTI respectively.

10952: 10778: 10627: 10385: 10105: 10023: 9938: 9913: 9898: 9836: 9788: 9768: 9693: 9688: 9673: 9414: 9346: 8777:

Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, et al. (October 2014).

8360: 8347:

Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al. (November 2011).

8303: 8025: 7844: 7833:"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy" 7785: 7398: 7290:

Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. (February 2009).

6468: 6312: 6209:

Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. (November 2001).

5941: 5248: 4543:

Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. (August 1999).

4069: 4011:

Gagliardo C, Brozovich A, Birnbaum J, Radix A, Foca M, Nelson J, et al. (March 2014).

3515: 2902: 2548:

Smyth RP, Davenport MP, Mak J (November 2012). "The origin of genetic diversity in HIV-1".

2493: 1378: 1260:

For cases where the woman is HIV positive and the man is HIV negative, the usual method is

1183: 1056: 858:

US DHHS guidelines are similar but include PI based options for children > 3 years old.

508: 472:

as an adjunct to antiretroviral therapy for adults with HIV. A Cochrane review included 25

334: 10209: 8421: 8349:"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield" 5333:"The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs" 3773:

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. (23 July 2014).

3072:

Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. (August 2015).

2019:"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents" 8: 10887: 10746: 10618: 10536: 10335: 10214: 10120: 10095: 10063: 9981: 9953: 9903: 9821: 9811: 9763: 9753: 9743: 9718: 9329: 9303: 7513: 6688: 6106:

Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, et al. (March 2000).

5794:

Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, et al. (July 2010).

5611: 4813:

Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP (April 2007).

3814: 3215:

Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. (October 2008).

1438: 1300: 1171: 710: 691: 500: 261: 33:. There are several classes of antiretroviral agents that act on different stages of the 8364: 8307: 8167:

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. (March 2017).

8029: 7848: 7789: 6472: 6316: 5945: 5559:

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. (May 2019).

5252: 4236:

Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, et al. (January 2013).

4073: 3519: 2497: 2457: 914:

that are multifactorial complications from HIV, associated behaviors, coinfections like

10110: 10100: 10008: 10003: 9976: 9963: 9948: 9933: 9883: 9846: 9831: 9783: 9778: 9758: 9728: 9703: 9663: 9655: 9587: 9582: 9451: 9376: 9278: 8980: 8955: 8936: 8847: 8822: 8721: 8696: 8677: 8614: 8589: 8537: 8510: 8481: 8454: 8430: 8405: 8381: 8348: 8324: 8291: 8267: 8242: 8193: 8168: 8144: 8119: 8095: 8070: 8046: 8013: 7989: 7962: 7913: 7865: 7832: 7808: 7773: 7749: 7724: 7723:

Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, et al. (November 2013).

7708: 7679: 7654: 7630: 7605: 7365: 7340: 7321: 7246: 7150: 7101: 6997: 6842: 6752: 6736: 6621: 6578: 6528: 6503: 6427: 6410: 6335: 6300: 6186: 6161: 6137: 6083: 6058: 6013: 5986: 5962: 5929: 5905: 5880: 5820: 5795: 5666: 5639: 5587: 5560: 5536: 5373: 5313: 5260: 5160: 5135: 5033: 5008: 4984: 4959: 4932: 4907: 4880: 4855: 4795: 4741: 4716: 4692: 4667: 4520: 4493: 4469: 4444: 4361: 4262: 4237: 4213: 4188: 4129: 4104: 4037: 4012: 3865: 3840: 3839:

Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. (December 2005).

3755: 3703: 3479: 3454: 3430: 3405: 3386: 3332: 3241: 3216: 3192: 3167: 3098: 3073: 3049: 3024: 2965: 2840: 2796: 2771: 2685: 2643: 2527: 2391: 2372: 2308: 2283: 2261: 2178: 2153: 2134: 2069: 2042: 1931: 1906: 1843: 1710:

Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors

1340: 1277: 1107:

Each class and individual antiretroviral carries unique risks of adverse side effects.

420: 250: 8924: 8795: 8778: 6652: 6276: 6251: 6177: 5577: 5524: 5416: 5399: 5082: 4349: 4187:

Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, et al. (October 2012).

3470: 2953: 2214: 1922: 785:

The WHO preferred initial regimen for adults and adolescents as of June 30, 2013, is:

37:

life-cycle. The use of multiple drugs that act on different viral targets is known as

11029: 10692: 10058: 9908: 9878: 9858: 9841: 9748: 9713: 9698: 9683: 9668: 9446: 9356: 9313: 9183: 9047: 8985: 8928: 8890: 8852: 8800: 8726: 8669: 8619: 8542: 8486: 8435: 8386: 8329: 8272: 8198: 8149: 8100: 8051: 7994: 7905: 7870: 7813: 7754: 7684: 7635: 7586: 7370: 7313: 7265: 7250: 7238: 7142: 7093: 7058: 7048: 6989: 6954: 6913: 6886: 6834: 6829: 6812: 6793: 6744: 6692: 6656: 6613: 6570: 6533: 6484: 6432: 6391: 6357: 6340: 6281: 6232: 6211:"Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase" 6191: 6129: 6088: 6018: 5967: 5910: 5861: 5825: 5776: 5671: 5592: 5528: 5421: 5354: 5349: 5332: 5317: 5305: 5264: 5165: 5038: 4989: 4937: 4885: 4836: 4787: 4746: 4697: 4620: 4566: 4525: 4474: 4425: 4353: 4318: 4267: 4218: 4167: 4134: 4085: 4042: 3993: 3952: 3911: 3870: 3796: 3747: 3695: 3648: 3610: 3533: 3484: 3435: 3378: 3374: 3324: 3246: 3197: 3148: 3103: 3054: 3000: 2957: 2922: 2884: 2832: 2828: 2801: 2752: 2677: 2606: 2565: 2519: 2434: 2396: 2376: 2339: 2313: 2253: 2218: 2183: 2126: 2074: 1936: 1887: 1835: 1793: 1788: 1771: 1636: 1485: 1236: 1155:

NNRTIs are generally safe and well tolerated. The main reason for discontinuation of

1128: 940: 935: 886: 875: 862: 574: 385: 174: 8940: 8886: 8752: 8681: 8605: 7917: 7325: 7154: 7105: 7001: 6846: 6756: 6625: 6141: 5540: 5105:"New one-pill, $ 10-per-month anti-retroviral AIDS treatment debuts in South Africa" 4958:

Eshun-Wilson I, Siegfried N, Akena DH, Stein DJ, Obuku EA, Joska JA (January 2018).

4365: 3759: 3707: 3336: 2969: 2689: 2531: 2430: 2265: 2138: 1847: 432:

expectancy and leaves more drugs available to the individual should the need arise.

11054: 10115: 9893: 9873: 9868: 9798: 9733: 9476: 9037: 8975: 8971: 8967: 8920: 8882: 8842: 8834: 8790: 8716: 8708: 8661: 8609: 8601: 8532: 8522: 8476: 8466: 8425: 8417: 8376: 8368: 8319: 8311: 8262: 8254: 8188: 8180: 8139: 8131: 8090: 8082: 8041: 8033: 7984: 7974: 7897: 7860: 7852: 7803: 7793: 7744: 7736: 7674: 7666: 7625: 7617: 7576: 7360: 7352: 7303: 7230: 7132: 7085: 7040: 6981: 6944: 6876: 6824: 6783: 6728: 6684: 6648: 6605: 6582: 6560: 6523: 6515: 6476: 6422: 6381: 6371: 6330: 6320: 6271: 6263: 6222: 6181: 6173: 6119: 6078: 6074: 6070: 6008: 5998: 5957: 5949: 5900: 5892: 5853: 5815: 5807: 5768: 5661: 5651: 5582: 5572: 5520: 5411: 5344: 5297: 5256: 5155: 5147: 5028: 5020: 4979: 4975: 4971: 4927: 4919: 4875: 4867: 4826: 4799: 4777: 4736: 4728: 4687: 4679: 4610: 4600: 4556: 4515: 4505: 4464: 4456: 4417: 4345: 4308: 4298: 4257: 4249: 4208: 4200: 4124: 4120: 4116: 4077: 4032: 4024: 3983: 3942: 3901: 3860: 3852: 3786: 3737: 3687: 3600: 3523: 3474: 3466: 3453:

Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD (November 2013).

3425: 3417: 3390: 3370: 3314: 3236: 3228: 3187: 3179: 3138: 3130: 3093: 3085: 3044: 3036: 2949: 2940:

Harrington M, Carpenter CC (June 2000). "Hit HIV-1 hard, but only when necessary".

2914: 2874: 2824: 2791: 2787: 2783: 2744: 2669: 2596: 2561: 2557: 2511: 2426: 2386: 2368: 2303: 2295: 2245: 2210: 2173: 2165: 2118: 2064: 2054: 1926: 1918: 1877: 1827: 1815: 1783: 1772:"Natural history of HIV infection in the era of combination antiretroviral therapy" 1747: 1677: 1611: 1578: 1536: 1265: 1214: 1027: 124: 11228: 8638: 7033:

Institute of Medicine (US) Committee for the Oversight of AIDS Activities (1988).

6267: 3528: 3503: 3272:"First long-acting injectable antiretroviral therapy for HIV recommended approval" 2844: 2515: 2152:

Beccari MV, Mogle BT, Sidman EF, Mastro KA, Asiago-Reddy E, Kufel WD (June 2019).

1619:

phase 1 clinical trial of an HIV mRNA vaccine (mRNA-1644) starting later in 2021.

11255: 11130: 11089: 10249: 9626: 9366: 9136: 7798: 7563:

Kang H, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II (December 2015).

6609: 6565: 6552: 6325: 6003: 5896: 5811: 5331:

Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA (May 1999).

5024: 4871: 4782: 4765: 4732: 4715:

May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. (May 2014).

4081: 3742: 3725: 3319: 3302: 3232: 2748: 2299: 1645: 1344: 1124: 1081: 847:

and for children 3 years to less than 10 years and adolescents <35 kilograms:

775: 9042: 9025: 7234: 7137: 6788: 6771: 4561: 4544: 3856: 2918: 2879: 2862: 730:(two NRTIs) and dolutegravir for patients who have been tested negative for the 45:). HAART decreases the patient's total burden of HIV, maintains function of the 11204: 10210: 9577: 9361: 8258: 8184: 7939: 6480: 6124: 6107: 5635: 4831: 4814: 2772:"Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults" 2601: 2584: 1631: 1516: 1434: 1409: 1398: 1390: 1365: 614:

guidelines. In Europe there are the European AIDS Clinical Society guidelines.

560: 553: 54: 26: 8838: 8712: 8665: 8471: 8086: 7537:"HIV patient seemingly cured in second remarkable case, London doctors report" 7339:

Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. (March 2014).

7120: 6931:

Savasi V, Ferrazzi E, Lanzani C, Oneta M, Parrilla B, Persico T (March 2007).

6386: 5772: 4510: 4388:. US Department of Health and Human Services. 12 February 2014. pp. 50–61 4164:

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

3726:"Risk of cancers during interrupted antiretroviral therapy in the SMART study" 2673: 2249: 2122: 2059: 53:

that often lead to death. HAART also prevents the transmission of HIV between

11265: 10970: 10720: 10555: 10441: 9557: 9466: 8290:

Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. (April 2013).

7341:"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV" 6933:"Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples" 6596:

Lee FJ, Carr A (September 2012). "Tolerability of HIV integrase inhibitors".

5727: 5136:"Cost-effectiveness of HIV treatment as prevention in serodiscordant couples" 3988: 3971: 3556: 1967: 1861: 1544: 1520: 1504: 1442: 1429: 1382: 1246: 907: 903: 748:(inhibiting metabolism of the former) in patients with good kidney function ( 565: 469: 199: 65: 46: 8527: 8372: 8037: 7888:

Carcelain G, Autran B (July 2013). "Immune interventions in HIV infection".

7725:"Absence of detectable HIV-1 viremia after treatment cessation in an infant" 7621: 7292:"Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation" 7034: 6949: 6932: 6881: 6864: 5953: 5709: 4383:"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" 3025:"Effect of early versus deferred antiretroviral therapy for HIV on survival" 1831: 1752: 1735: 1705:

Discovery and development of non-nucleoside reverse-transcriptase inhibitors

1606:

series of different immunogens with the goal of eventually inducing bnAb(s).

1476:

is an active area of research and an important tool for managing the global

617:

For resource limited countries, most national guidelines closely follow the

11024: 11014: 10595: 10585: 10403: 10360: 10355: 10350: 10312: 10292: 10222: 9592: 9283: 9051: 8989: 8932: 8894: 8856: 8804: 8730: 8673: 8623: 8546: 8490: 8439: 8390: 8333: 8276: 8243:"HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens" 8202: 8153: 8104: 8055: 7998: 7909: 7874: 7817: 7758: 7688: 7639: 7590: 7482: 7374: 7317: 7242: 7062: 6993: 6958: 6890: 6838: 6748: 6617: 6574: 6537: 6519: 6488: 6436: 6395: 6344: 6285: 6236: 6227: 6210: 6195: 6133: 6092: 6022: 5971: 5914: 5865: 5829: 5736: 5675: 5596: 5532: 5425: 5358: 5309: 5301: 5169: 5042: 4993: 4941: 4923: 4889: 4840: 4791: 4766:"Life expectancy living with HIV: recent estimates and future implications" 4750: 4701: 4624: 4570: 4529: 4478: 4429: 4357: 4322: 4271: 4222: 4138: 4089: 4046: 3997: 3956: 3915: 3874: 3800: 3791: 3774: 3751: 3699: 3614: 3605: 3537: 3488: 3439: 3382: 3328: 3250: 3201: 3152: 3143: 3107: 3058: 2961: 2805: 2756: 2681: 2630: 2569: 2438: 2400: 2317: 2257: 2222: 2187: 2130: 2078: 1940: 1891: 1882: 1865: 1839: 1797: 1574: 1481: 1187: 1163:

can cause severe hepatotoxicity, especially in women with high CD4 counts.

1120: 1092: 741: 717: 532: 354: 290: 282: 278: 8071:"HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation" 7979: 7740: 7356: 7308: 7291: 7146: 7097: 6917: 6797: 6696: 6660: 5780: 5656: 5616:. AIDS2018: 22nd International AIDS Conference. Amsterdam, the Netherlands 5268: 5151: 5007:

Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR (June 2009).

4815:"Older age and the response to and tolerability of antiretroviral therapy" 4460: 4421: 4313: 4253: 3421: 3134: 3089: 3074:"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection" 3040: 2926: 2888: 2836: 2610: 2523: 889:

having a lower risk than vaginal delivery or emergency Caesarian section.

648:

The newest WHO guidelines (dated September 30, 2015) now agree and state:

151:. Ibalizumab is effective against both CCR5 and CXCR4 tropic HIV viruses. 11150: 11125: 11064: 11049: 11044: 10708: 10675: 10590: 10570: 10365: 10345: 10324: 10271: 10239: 9496: 9397: 9188: 8406:"Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design" 8292:"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus" 8135: 7581: 7564: 6376: 6359: 4615: 4445:"Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children" 4204: 4028: 3947: 3930: 3691: 2169: 1598: 1564: 1224: 1140: 919: 915: 731: 706: 587: 528: 443:

promoting the advancement of single-pill antiretroviral drug combinations

404: 286: 273: 246: 158: 144: 132: 8315: 7856: 6553:"Protease inhibitor-based regimens for HIV therapy: safety and efficacy" 5609: 5060: 11155: 11135: 11120: 11115: 11079: 11074: 10988: 10933: 10903: 10715: 10703: 10698: 10670: 10610: 10600: 10575: 10560: 10550: 10499: 10494: 10482: 10466: 10456: 10436: 10398: 10308: 10296: 10288: 9456: 9298: 9126: 5377: 4856:"Virologic and immunologic response to HAART, by age and regimen class" 1512: 1511:

like HIV, the spike protein is formed by two proteins expressed by the

1508: 1446: 1281: 1160: 1004: 833: 790: 779: 745: 727: 667: 549: 412: 400: 396: 330: 318: 314: 242: 234: 195: 187: 171: 167: 136: 112: 83:(WHO) recommend offering antiretroviral treatment to all patients with 7901: 6985: 6740: 5732:"End to AIDS in sight as huge study finds drugs stop HIV transmission" 5330: 4908:"Management of human immunodeficiency virus infection in advanced age" 2819:

Darbyshire J (1995). "Perspectives in drug therapy of HIV infection".

2040: 11165: 11145: 11140: 11110: 11039: 11019: 10908: 10665: 10580: 10565: 10488: 10461: 10451: 10446: 10393: 10370: 10283: 8636: 7541: 7450:"2016 Towards an HIV Cure Symposium Programme. 16 & 17 July 2016" 5478:"The science is clear: with HIV, undetectable equals untransmittable" 4492:

Adetokunboh OO, Schoonees A, Balogun TA, Wiysonge CS (October 2015).

2988: 1462: 1458: 1449:

have been used in human trials with only preliminary results so far.

1372:

that replaced his immune system with a donor's that did not have the

1332: 1308: 1304: 1175: 1156: 1076: 760: 756: 663: 504: 408: 377: 338: 326: 322: 310: 306: 265: 238: 203: 128: 9065: 7670: 6716: 5057:"Global Price Reporting Mechanism for HIV, tuberculosis and malaria" 3970:

Sungkanuparph S, Pasomsub E, Chantratita W (January–February 2014).

2734: 2360: 2043:"Beyond viral suppression of HIV - the new quality of life frontier" 1547:, whose function is to memorize the characteristics of the original 11160: 10545: 9562: 9461: 9158: 9106: 6732: 5857: 4683: 4605: 4588: 4491: 4303: 4286: 4160:"Antiretroviral Therapy for Human Immunodeficiency Virus Infection" 3906: 3889: 3183: 2284:"HIV-1 reverse transcriptase and antiviral drug resistance. Part 1" 1540: 1528: 1496: 1402: 1394: 1320: 1136: 1068: 911: 851: 723: 556: 207: 191: 103: 30: 9071: 7425:"No trace of HIV virus after successful stem cell transplantation" 4335: 3976:

Journal of the International Association of Providers of AIDS Care

552:(<50 copies/ml) has sex with a partner who is HIV negative. In 213: 11059: 10605: 10375: 9486: 7044: 6903: 5713: 5640:"Antiretroviral Therapy for the Prevention of HIV-1 Transmission" 5214: 3619:

PARTNER (Partners of People on ART—A New Evaluation of the Risks)

3588: 3406:"Prevention of HIV-1 infection with early antiretroviral therapy" 2708: 1694: 1548: 1084:, and when six or more drugs are needed it is termed mega-HAART. 425: 361: 342: 139:

are available agents in this class. Maraviroc works by targeting

6162:"HIV/AIDS epidemiology, pathogenesis, prevention, and treatment" 5985:

Chung CY, Alden SL, Funderburg NT, Fu P, Levine AD (June 2014).

5927: 5509: 4812: 3969: 1288:(NRTI), was not effective on its own. It was approved by the US 11009: 11004: 9602: 8953: 6769: 5842: 5239:

Beardsley T (July 1998). "Coping with HIV's ethical dilemmas".

4957: 4010: 2483: 2453:"Myriad Genetics suspends its HIV maturation inhibitor program" 1532: 1335:

technology, but with the later irrelevance of the distinction,

1323:

process is linguistically comparable to the way that the words

735: 8240: 7960: 5371: 4665: 4238:"Short-course antiretroviral therapy in primary HIV infection" 4102: 2582: 147:

which allows HIV to target an alternative co-receptor such as

10319: 9518:

European and Developing Countries Clinical Trials Partnership

9026:"Current status of gene therapy strategies to treat HIV/AIDS" 8169:"Modified mRNA Vaccines Protect against Zika Virus Infection" 7830: 6036: 5878: 5757: 4960:"Antidepressants for depression in adults with HIV infection" 3928: 2983:

Sonenklar C (2011). "Chapter 6: Treatment for HIV and AIDS".

843:

abacavir (or zidovudine) + lamivudine + lopinivir + ritonivir

687: 440: 381: 148: 9023: 8455:"The expanding array of HIV broadly neutralizing antibodies" 7652: 6714: 6105: 5006: 4905: 4586: 3673:"CD4+ count-guided interruption of antiretroviral treatment" 3022: 2416: 10833:

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

10278: 10266: 9636: 9597: 8637:

International AIDS Vaccine Initiative (29 September 2021).

6056: 5558: 4906:

Greene M, Justice AC, Lampiris HW, Valcour V (April 2013).

4284: 3670: 3586: 2367:. Advances in Pharmacology. Vol. 67. pp. 75–105. 2361:"HIV integrase inhibitors: 20-year landmark and challenges" 1373: 1116: 1026:

This result is consistent with the conclusion presented by

816:

associated with lower risk of transmission (See section on

679: 140: 10838:

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil

7289: 6930: 6298: 6059:"Antiretroviral resistance testing in HIV-positive people" 5133: 4442: 4285:

Hollingsworth TD, Anderson RM, Fraser C (September 2008).

4059: 3300: 3214: 3165: 3071: 2277: 2275: 1159:

is neuro-psychiatric effects including suicidal ideation.

10303: 10218: 9121: 9102: 8776: 8346: 7771: 7118: 4582: 4580: 3723: 2991:

Health Reports: Diseases and Disorders. Minneapolis, MN:

2200: 1601:, which can secrete the broadly neutralizing antibodies: 1500: 477: 369: 365: 84: 34: 10784:

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide

9201:

WHO disease staging system for HIV infection and disease

8166: 8117: 7704:"Early Treatment Is Found to Clear H.I.V. in a 2nd Baby" 6862: 4853: 4406: 4235: 3887: 3452: 3349: 2412: 2410: 2151: 1813: 1648:, who died in 1991, aged 45, of AIDS-related pneumonia. 633:

The US DHHS guidelines (published April 8, 2015) state:

8118:

Pardi N, Hogan MJ, Porter FW, Weissman D (April 2018).

7562: 6865:"Reproductive assistance in HIV serodiscordant couples" 5634: 5286: 4714: 4542: 3504:"Breakthrough of the year. HIV treatment as prevention" 3403: 2860: 2358: 2272: 489: 219:

Non-nucleoside reverse-transcriptase inhibitors (NNRTI)

10169:

List of HIV/AIDS cases and deaths registered by region

7722: 6971: 6810: 5984: 5610:

Rodger, A. (for the PARTNER study group) (July 2018).

4953: 4951: 4577: 3120: 1736:"A universal CAR-NK cell approach for HIV eradication" 159:

Nucleoside/nucleotide reverse-transcriptase inhibitors

11239: 8651: 7191: 7189: 7016:"U.S Approves Drug to Prolong Lives of AIDS Patients" 6249: 5793: 5486:

National Institute of Allergy and Infectious Diseases

3838: 2407: 1907:"The end of AIDS: HIV infection as a chronic disease" 1408:

In March 2019, a second patient, referred to as the "

1123:

DNA synthesis and lead to high levels of lactate and

1087: 1032:

National Institute of Allergy and Infectious Diseases

70:

National Institute of Allergy and Infectious Diseases

8910: 8820: 6673: 3772: 2823:. 49 Suppl 1 (Supplement 1): 1–3, discussion 38–40. 2659: 1700:

Discovery and development of HIV-protease inhibitors

1331:

at first were needed to make useful distinctions in

459:), and thus their effectiveness over the long-term. 10164:

List of countries by HIV/AIDS adult prevalence rate

9553:

President's Emergency Plan for AIDS Relief (PEPFAR)

9538:

Joint United Nations Programme on HIV/AIDS (UNAIDS)

8068: 7338: 7166: 7164: 6159: 4948: 4763: 2939: 2769: 839:The WHO recommends for children less than 3 years: 453:

More than 20 antiretroviral fixed-dose combinations

8587: 7217: 7186: 6208: 6037:"Stanford University HIV Drug Resistance Database" 5372:Swiss National AIDS Commission (15 October 2016). 2905:(August 1995). "Time to hit HIV, early and hard". 1359: 1202: 428:, which limits the number of useful combinations. 6559:. 45 Suppl 1 (Supplement 1): S5–13, quiz S28–31. 6408: 5503: 5185:"Activists Protest Stribild's $ 28,500 Price Tag" 4186: 2547: 11263: 10790:Dolutegravir/emtricitabine/tenofovir alafenamide 8872: 8403: 8289: 7487:National AIDS Treatment Advocacy Project (NATAP) 7399:"HIV cure study provides insight into 2008 case" 7161: 5698:. British HIV Association Autumn Conference 2017 5692:U=U: Talking to patients about transmission risk 5554: 5552: 5550: 1904: 678:Most HAART regimens consist of three drugs: Two 10848:Emtricitabine/rilpivirine/tenofovir alafenamide 10768:Bictegravir/emtricitabine/tenofovir alafenamide 9152:National Addiction and HIV Data Archive Program 7887: 6863:Savasi V, Mandia L, Laoreti A, Cetin I (2012). 6817:Journal of Acquired Immune Deficiency Syndromes 6557:Journal of Acquired Immune Deficiency Syndromes 6501: 6250:Birkus G, Hitchcock MJ, Cihlar T (March 2002). 4764:Nakagawa F, May M, Phillips A (February 2013). 1905:Deeks SG, Lewin SR, Havlir DV (November 2013). 1038:, and his team in a viewpoint published in the 333:are recommended as first line therapy choices. 221:inhibit reverse transcriptase by binding to an 214:Non-nucleoside reverse-transcriptase inhibitors 10853:Emtricitabine/rilpivirine/tenofovir disoproxil 10339:(Integrase strand transfer inhibitors (INSTI)) 8588:Jones LD, Moody MA, Thompson AB (March 2020). 8069:Checkley MA, Luttge BG, Freed EO (July 2011). 6858: 6856: 6409:Hart AB, Samuels DC, Hulgan T (October 2013). 6160:Simon V, Ho DD, Abdool Karim Q (August 2006). 5397: 4587:European Collaborative Study (February 2005). 2933: 2336:Antiretroviral Resistance in Clinical Practice 10801:Dolutegravir/lamivudine/tenofovir alafenamide 10195: 9087: 9068:at US Department of Health and Human Services 8511:"HIV mRNA Vaccines-Progress and Future Paths" 7932:"Programs TAT – Vaccin VIH | BIOSANTECH SA ®" 7075: 6502:Usach I, Melis V, Peris JE (September 2013). 6458: 5725: 5547: 4166:(7th ed.). Churchill Livingstone. 2009. 3018: 3016: 2976: 2235: 1769: 1280:sprang up since 1986 to combat HIV. The drug 10823:Efavirenz/emtricitabine/tenofovir disoproxil 10807:Dolutegravir/lamivudine/tenofovir disoproxil 8697:"FDA warning to manufacturers of AIDS drugs" 8508: 8011: 7396: 5111:. Agence France-Presse. 2013. Archived from 2108: 1860: 1809: 1807: 1651: 817: 364:to correct errors made when it converts its 116:transfer inhibitors or INSTIs) as a "base". 9244:Diffuse infiltrative lymphocytosis syndrome 8960:The Cochrane Database of Systematic Reviews 8821:Gakhar H, Kamali A, Holodniy M (May 2013). 7603: 7220:"HIV cure research: advances and prospects" 7195: 6965: 6906:MMWR. Morbidity and Mortality Weekly Report 6853: 6721:Infection Control and Hospital Epidemiology 6063:The Cochrane Database of Systematic Reviews 5232: 5059:. World Health Organization. Archived from 4964:The Cochrane Database of Systematic Reviews 4287:"HIV-1 transmission, by stage of infection" 4109:The Cochrane Database of Systematic Reviews 3582: 3580: 3578: 3495: 2856: 2854: 2776:The Cochrane Database of Systematic Reviews 2770:Onwumeh J, Okwundu CI, Kredo T (May 2017). 2576: 1041:Journal of the American Medical Association 10818:Doravirine/lamivudine/tenofovir disoproxil 10202: 10188: 9477:People With AIDS Self-Empowerment Movement 9094: 9080: 8509:Mu Z, Haynes BF, Cain DW (February 2021). 8120:"mRNA vaccines - a new era in vaccinology" 5471: 5469: 5467: 5465: 3559:. Prevention Access Campaign. 21 July 2016 3013: 2818: 2812: 2626:"Attacking AIDS with a 'cocktail' therapy" 2359:Métifiot M, Marchand C, Pommier Y (2013). 1733: 1468: 1286:nucleoside reverse-transcriptase inhibitor 542: 10828:Efavirenz/lamivudine/tenofovir disoproxil 9041: 8979: 8846: 8794: 8720: 8613: 8536: 8526: 8480: 8470: 8429: 8380: 8323: 8266: 8192: 8143: 8094: 8045: 7988: 7978: 7864: 7807: 7797: 7748: 7678: 7629: 7580: 7364: 7307: 7263: 7136: 6948: 6880: 6828: 6787: 6564: 6527: 6508:Journal of the International AIDS Society 6426: 6385: 6375: 6364:The Journal of Antimicrobial Chemotherapy 6334: 6324: 6275: 6226: 6185: 6123: 6082: 6012: 6002: 5961: 5904: 5819: 5665: 5655: 5586: 5576: 5415: 5348: 5238: 5159: 5032: 4983: 4931: 4879: 4830: 4781: 4740: 4691: 4614: 4604: 4560: 4519: 4509: 4468: 4312: 4302: 4261: 4212: 4128: 4036: 3987: 3946: 3935:The Journal of Antimicrobial Chemotherapy 3905: 3864: 3790: 3741: 3604: 3527: 3478: 3429: 3364: 3318: 3266: 3264: 3262: 3260: 3240: 3191: 3142: 3097: 3048: 2982: 2878: 2795: 2600: 2505: 2390: 2307: 2281: 2177: 2068: 2058: 1930: 1881: 1804: 1787: 1751: 1356:further research towards a cure for HIV. 1264:. With appropriate treatment the risk of 1193: 929: 11095:Zinc finger protein transcription factor 8694: 7422: 7218:Passaes CP, Sáez-Cirión A (April 2014). 6550: 5603: 3575: 2851: 1166: 1072:who have not done any treatment before. 434: 305:Examples of HIV protease inhibitors are 102: 98: 8906: 8904: 8868: 8866: 8816: 8814: 8772: 8770: 8558: 8556: 8504: 8502: 8500: 7506: 7213: 7211: 7209: 7090:10.7326/0003-4819-124-7-199604010-00003 6974:Expert Review of Anti-Infective Therapy 6595: 6155: 6153: 6151: 5628: 5475: 5462: 2333: 1047: 612:Department of Health and Human Services 610:the US) as well as the US government's 594:load less than 200 copies/ml was zero. 484: 256: 77:Department of Health and Human Services 11264: 7701: 7266:"The Man Who Had HIV and Now Does Not" 6710: 6708: 6706: 5688: 5282: 5280: 5278: 4770:Current Opinion in Infectious Diseases 3719: 3717: 3666: 3664: 3551: 3549: 3547: 3257: 2895: 2623: 2329: 2327: 1770:Moore RD, Chaisson RE (October 1999). 1622: 974: 797: 656: 348: 296: 253:is intrinsically resistant to NNRTIs. 25:normally includes the use of multiple 10183: 9513:Discredited HIV/AIDS origins theories 9075: 8590:"Innovations in HIV-1 Vaccine Design" 8452: 8422:10.1146/annurev-immunol-041015-055515 7480: 6256:Antimicrobial Agents and Chemotherapy 4901: 4899: 4636: 4634: 4377: 4375: 4193:Antimicrobial Agents and Chemotherapy 4154: 4152: 4150: 4148: 3637: 3635: 3633: 3631: 3629: 3627: 3501: 2655: 2653: 2640:US Dept. of Health and Human Services 2543: 2541: 2158:Antimicrobial Agents and Chemotherapy 2104: 2102: 2100: 2098: 2096: 2094: 2092: 2090: 2088: 2036: 2034: 2032: 2030: 2028: 2013: 2011: 2009: 2007: 2005: 1954: 1952: 1950: 1616:International AIDS Vaccine Initiative 1571:Broadly neutralizing HIV-1 antibodies 1230: 979: 880:Breastfeeding by HIV infected mothers 809: 8901: 8863: 8811: 8767: 8737: 8553: 8497: 8404:Burton DR, Hangartner L (May 2016). 7206: 6689:10.1001/archinte.1993.00410120035005 6638: 6148: 5182: 4410:AIDS Research and Human Retroviruses 2017: 2003: 2001: 1999: 1997: 1995: 1993: 1991: 1989: 1987: 1985: 1765: 1763: 1581:(antibody-mediated) immunity, but a 1452: 1245:used to prevent HIV transmission is 1209:Post-exposure prophylaxis § HIV 604: 490:Initiation of antiretroviral therapy 462: 39:highly active antiretroviral therapy 10843:Emtricitabine/tenofovir alafenamide 9632:The Freddie Mercury Tribute Concert 9101: 8012:Haynes BF, Burton DR (March 2017). 7729:The New England Journal of Medicine 7534: 7345:The New England Journal of Medicine 7296:The New England Journal of Medicine 7125:The New England Journal of Medicine 6776:The New England Journal of Medicine 6703: 6461:Toxicology and Applied Pharmacology 6215:The Journal of Biological Chemistry 5644:The New England Journal of Medicine 5275: 5140:The New England Journal of Medicine 4549:The New England Journal of Medicine 4449:The New England Journal of Medicine 4242:The New England Journal of Medicine 3714: 3680:The New England Journal of Medicine 3661: 3544: 3410:The New England Journal of Medicine 3123:The New England Journal of Medicine 3078:The New England Journal of Medicine 3029:The New England Journal of Medicine 2907:The New England Journal of Medicine 2867:The New England Journal of Medicine 2324: 1423: 1296:The New England Journal of Medicine 1075:If there is extensive resistance a 119: 68:, former head of the United States 13: 10858:Emtricitabine/tenofovir disoproxil 9017: 5761:The Journal of Infectious Diseases 5261:10.1038/scientificamerican0798-106 4896: 4672:The Journal of Infectious Diseases 4631: 4372: 4291:The Journal of Infectious Diseases 4145: 3624: 2901: 2650: 2589:The Journal of Infectious Diseases 2538: 2373:10.1016/B978-0-12-405880-4.00003-2 2085: 2025: 1947: 1676:Food insecurity is a major public 1667: 1102: 1088:Structured treatment interruptions 1062: 802: 582:award to treatment as prevention. 380:either are inferior to the parent 14: 11293: 9218:Countries by AIDS prevalence rate 9059: 5450:from the original on 7 April 2019 4062:Infection, Genetics and Evolution 3647:. WHO. 30 June 2013. p. 38. 1982: 1760: 869: 11249: 11231:. Formerly or rarely used agent. 10868:Lamivudine/nevirapine/zidovudine 10752:Abacavir/dolutegravir/lamivudine 9679:Democratic Republic of the Congo 9239:AIDS-defining clinical condition 8996: 8947: 8688: 8645: 8630: 8581: 8446: 8397: 8340: 8283: 8234: 8209: 8160: 8111: 8062: 8005: 7954: 7924: 7881: 7824: 7765: 7716: 7695: 7646: 7597: 7569:Molecular Therapy. Nucleic Acids 7556: 7528: 7500: 7474: 7442: 7416: 7390: 7381: 7332: 7283: 7257: 7112: 7069: 7026: 7008: 6924: 6897: 6830:10.1097/00126334-200012010-00008 6804: 6763: 6667: 6641:The American Journal of Medicine 6632: 6589: 6544: 6495: 6452: 6443: 6402: 6351: 6292: 6243: 6202: 6099: 6050: 6029: 5978: 5398:The Lancet Hiv (November 2017). 5350:10.1097/00002030-199905070-00008 3375:10.1097/00002030-200001280-00006 3281:(Press release). 16 October 2020 2829:10.2165/00003495-199500491-00003 2737:The American Journal of Medicine 1866:"Toward an AIDS-free generation" 1789:10.1097/00002030-199910010-00017 1488:may provide a new path forward. 926:(HPV) as well as HIV treatment. 394:reverse-transcriptase inhibitors 184:competitive substrate inhibitors 11035:Epigallocatechin gallate (EGCG) 10878:Lamivudine/tenofovir disoproxil 10863:Lamivudine/nevirapine/stavudine 8887:10.1016/j.socscimed.2007.03.015 8606:10.1016/j.clinthera.2020.01.009 7397:Senthilingam M (18 July 2016). 6598:Current Opinion in HIV and AIDS 5921: 5872: 5836: 5787: 5751: 5719: 5682: 5432: 5391: 5365: 5324: 5207: 5176: 5127: 5097: 5075: 5049: 5000: 4847: 4806: 4757: 4708: 4659: 4536: 4485: 4436: 4400: 4329: 4278: 4229: 4180: 4096: 4053: 4004: 3963: 3922: 3881: 3832: 3807: 3766: 3446: 3397: 3343: 3294: 3208: 3159: 3114: 3065: 2763: 2728: 2696: 2617: 2477: 2445: 2431:10.1016/j.antiviral.2009.10.003 2352: 2229: 2194: 2145: 1525:nanoparticles for drug delivery 1360:Patients cured of HIV infection 1203:Post-exposure prophylaxis (PEP) 934:Many factors may contribute to 896: 10758:Abacavir/lamivudine/zidovudine 8972:10.1002/14651858.CD010806.pub2 8124:Nature Reviews. Drug Discovery 6075:10.1002/14651858.CD006495.pub5 5712:for presentation on behalf of 4976:10.1002/14651858.CD008525.pub3 4121:10.1002/14651858.CD004246.pub4 2788:10.1002/14651858.CD009818.pub2 2562:10.1016/j.virusres.2012.06.015 2282:Das K, Arnold E (April 2013). 1898: 1854: 1727: 793:(or emtricitabine) + efavirenz 499:new class of antiretrovirals, 16:Medical management of HIV/AIDS 1: 9548:Misconceptions about HIV/AIDS 9528:International AIDS Conference 9482:HIV/AIDS in the porn industry 9425:Discrimination against people 8925:10.1016/S0140-6736(10)60832-X 8875:Social Science & Medicine 8796:10.1016/S2352-3018(14)70018-9 6677:Archives of Internal Medicine 6653:10.1016/s0002-9343(97)89441-7 6268:10.1128/aac.46.3.716-723.2002 6178:10.1016/S0140-6736(06)69157-5 5689:Hodson M (17 November 2017). 5578:10.1016/S0140-6736(19)30418-0 5525:10.1016/S2352-3018(18)30132-2 5482:National Institutes of Health 5476:Hoffman H (10 January 2019). 5417:10.1016/S2352-3018(17)30183-2 4819:Archives of Internal Medicine 4350:10.1016/S0140-6736(04)17140-7 3529:10.1126/science.334.6063.1628 3471:10.1016/S0140-6736(13)61998-4 2954:10.1016/S0140-6736(00)02388-6 2624:Henkel J (July–August 1999). 2516:10.1126/science.271.5255.1582 2461:. 8 June 2012. Archived from 2215:10.1016/S0149-2918(08)80048-3 2021:. Clinicalinfo. 8 April 2015. 1923:10.1016/S0140-6736(13)61809-7 1814:Eisinger RW, Dieffenbach CW, 1720: 1036:National Institutes of Health 744:(an integrase inhibitor) and 624: 225:of the enzyme; NNRTIs act as 9408:Catholic Church and HIV/AIDS 9289:HIV Drug Resistance Database 8075:Journal of Molecular Biology 7799:10.1371/journal.pone.0009390 7604:Charpentier E (April 2015). 7172:"A Timeline of HIV and AIDS" 6610:10.1097/COH.0b013e328356682a 6566:10.1097/QAI.0b013e3180600709 6326:10.1371/journal.pone.0043803 6004:10.1371/journal.ppat.1004198 5897:10.1016/j.immuni.2016.01.006 5846:Clinical Infectious Diseases 5812:10.1097/QAD.0b013e32833adbcf 5083:"Antiretroviral Drug Prices" 5025:10.1097/QAD.0b013e32832ba8ec 4872:10.1097/QAD.0b013e32833e6d14 4783:10.1097/QCO.0b013e32835ba6b1 4733:10.1097/QAD.0000000000000243 4593:Clinical Infectious Diseases 4082:10.1016/j.meegid.2013.02.002 4017:Clinical Infectious Diseases 3894:Clinical Infectious Diseases 3743:10.1097/QAD.0b013e3282ed6338 3320:10.1097/QAD.0b013e32801424bd 3233:10.1097/QAD.0b013e3283112b77 3172:Clinical Infectious Diseases 2749:10.1016/j.amjmed.2006.08.033 2712:. March 2011. Archived from 2636:Food and Drug Administration 2300:10.1016/j.coviro.2013.03.012 1610:A Phase 1 clinical trial by 1314:As HAART became widespread, 1268:can be reduced to below 1%. 1243:assisted reproductive method 716:tenofovir/emtricitabine and 705:tenofovir/emtricitabine and 474:randomized controlled trials 241:. 2nd generation NNRTIs are 186:. Examples of NRTIs include 7: 10633:Tenofovir alafenamide (TAF) 9709:Côte d'Ivoire (Ivory Coast) 9543:Media portrayal of HIV/AIDS 9472:List of HIV-positive people 9043:10.1016/j.ymthe.2005.01.020 8410:Annual Review of Immunology 8014:"Developing an HIV vaccine" 7423:Darmanin M (21 July 2016). 7264:Rosenberg T (29 May 2011). 7235:10.1016/j.virol.2014.02.021 7138:10.1056/NEJM199709113371101 7078:Annals of Internal Medicine 6789:10.1056/NEJM199711203372101 4562:10.1056/NEJM199908053410602 3857:10.1136/bmj.38665.534595.55 2919:10.1056/NEJM199508173330710 2880:10.1056/NEJM199709113371102 2288:Current Opinion in Virology 1740:AIMS Allergy and Immunology 1688: 1350: 1174:(PIs) are often given with 951: 823: 673: 268:, which is responsible for 10: 11298: 10628:Tenofovir disoproxil (TDF) 9609:Reports from the Holocaust 9533:International AIDS Society 9523:Elton John AIDS Foundation 8259:10.1016/j.chom.2021.05.012 8217:"The HIV Life Cycle | NIH" 8185:10.1016/j.cell.2017.02.017 7507:Johnson C (5 March 2019). 7196:Sifris D, Myhre J (2017), 6481:10.1016/j.taap.2006.12.013 6125:10.1177/135965350000500113 4832:10.1001/archinte.167.7.684 2993:Twenty-First Century Books 2334:Geretti, ed. (2006). "9". 1864:, Folkers GK (July 2012). 1271: 1234: 1206: 991:Prevention Access Campaign 873: 439:A 2016 advertisement from 227:non-competitive inhibitors 11188: 11103: 10997: 10979: 10961: 10943: 10924: 10917: 10896: 10737: 10684: 10658: 10649:Discovery and development 10641: 10524: 10512: 10475: 10429: 10420:Discovery and development 10412: 10384: 10334: 10256:Discovery and development 10248: 10230: 10159: 10129: 10081: 10049: 9999: 9990: 9962: 9797: 9654: 9645: 9568:Treatment Action Campaign 9505: 9390: 9322: 9284:Tuberculosis co-infection 9226: 9147:disease progression rates 9114: 8839:10.1007/s40265-013-0040-4 8713:10.1136/bmj.322.7295.1143 8666:10.1377/hlthaff.26.5.1392 8472:10.1186/s12977-018-0453-y 8453:McCoy LE (October 2018). 8087:10.1016/j.jmb.2011.04.042 6869:Human Reproduction Update 5183:Horn T (28 August 2012). 4511:10.1186/s12879-015-1183-6 3502:Cohen J (December 2011). 3277:European Medicines Agency 2704:"Fixed-dose combinations" 2674:10.1007/s11904-007-0010-0 2250:10.1007/s00726-012-1394-8 2123:10.1080/09540120802511877 2060:10.1186/s12916-016-0640-4 1964:World Health Organization 1652:Beyond medical management 1641:misleading advertisements 1266:mother-to-child infection 1251:intrauterine insemination 1150: 1097:post-exposure prophylaxis 755:tenofovir/emtricitabine, 740:tenofovir/emtricitabine, 619:World Health Organization 525:European Medicines Agency 81:World Health Organization 29:as a strategy to control 10945:Transcription inhibitors 10897:Pharmacokinetic boosters 10813:Dolutegravir/rilpivirine 10774:Cabotegravir/rilpivirine 10414:Protease Inhibitors (PI) 9294:Innate resistance to HIV 9264:Neurocognitive disorders 7481:Levin J (19 July 2016). 6551:Walmsley S (June 2007). 5400:"U=U taking off in 2017" 4647:. US DHHS. 28 March 2014 3989:10.1177/2325957413488200 2662:Current HIV/AIDS Reports 2602:10.1093/infdis/174.5.962 1495:, the virus that causes 1220:US Public Health Service 1110: 854:+ lamivudine + efavirenz 720:(an integrase inhibitor) 580:Breakthrough of the Year 570:Pre-exposure prophylaxis 51:opportunistic infections 11229:initial regimen options 10795:Dolutegravir/lamivudine 10272:Enfuvirtide (ENF, T-20) 10250:Entry/fusion inhibitors 9615:AIDS–Holocaust metaphor 9598:Gay Men's Health Crisis 9274:Opportunistic infection 8695:Josefson D (May 2001). 8528:10.3390/vaccines9020134 8373:10.1126/science.1213256 8247:Cell Host & Microbe 8038:10.1126/science.aan0662 7622:10.15252/emmm.201504847 7610:EMBO Molecular Medicine 5954:10.1126/science.1222551 5773:10.1093/infdis/169.1.28 4498:BMC Infectious Diseases 1832:10.1001/jama.2018.21167 1753:10.3934/Allergy.2021015 1474:HIV vaccine development 1469:Sequential mRNA Vaccine 1370:bone marrow transplants 1316:fixed dose combinations 1262:artificial insemination 1000:British HIV Association 818:treatment as prevention 543:Treatment as prevention 449:fixed-dose combinations 11282:Prevention of HIV/AIDS 11070:Portmanteau inhibitors 10963:Translation inhibitors 10873:Lamivudine/raltegravir 10643:Non-nucleoside (NNRTI) 10601:Islatravir (EFdA, ISL) 9442:HIV-affected community 9382:HIV and homosexual men 7535:May A (5 March 2019). 6520:10.7448/ias.16.1.18567 6228:10.1074/jbc.M106743200 5444:Terrence Higgins Trust 5302:10.1001/jama.2012.7961 4924:10.1001/jama.2013.2963 3815:"EACS Guidelines 12.0" 3792:10.1001/jama.2014.8722 3606:10.1001/jama.2016.5148 1883:10.1001/jama.2012.8142 1734:Arachchige AS (2021). 1608: 1561:evolutionary arms race 1557:adaptive immune system 1399:antiretroviral therapy 1255:in vitro fertilization 1030:, the Director of the 1024: 1010:Terrence Higgins Trust 930:Adults with depression 444: 108: 64:is increasingly rare. 23:management of HIV/AIDS 11085:Synergistic enhancers 10883:Lamivudine/zidovudine 10763:Atazanavir/cobicistat 10739:Combined formulations 10576:Zidovudine (AZT, ZDV) 10514:Reverse-transcriptase 10386:Maturation inhibitors 9622:Silence=Death Project 9420:Criminal transmission 9340:Multiple sex partners 8594:Clinical Therapeutics 7980:10.1186/1742-4690-3-8 7890:Immunological Reviews 7741:10.1056/NEJMoa1302976 7357:10.1056/NEJMoa1300662 7309:10.1056/NEJMoa0802905 6950:10.1093/humrep/del422 6882:10.1093/humupd/dms046 5657:10.1056/NEJMoa1600693 5374:"The Swiss statement" 5152:10.1056/NEJMsa1214720 4461:10.1056/NEJMoa1113249 4422:10.1089/aid.2009.0054 4254:10.1056/NEJMoa1110039 3422:10.1056/NEJMoa1105243 3135:10.1056/NEJMoa1507198 3090:10.1056/NEJMoa1506816 3041:10.1056/NEJMoa0807252 2203:Clinical Therapeutics 1715:HIV capsid inhibition 1603: 1591:reverse transcription 1420:gene editing system. 1235:Further information: 1207:Further information: 1186:and elevated risk of 1133:peripheral neuropathy 1057:Innate lymphoid cells 1019: 924:human papilloma virus 644:psychosocial factors. 438: 374:reverse transcription 335:Maturation inhibitors 231:reverse transcriptase 180:reverse transcriptase 106: 99:Classes of medication 11272:Antiretroviral drugs 10926:Uncoating inhibitors 10779:Darunavir/cobicistat 10619:Nucleotide analogues 10537:Nucleoside analogues 10336:Integrase inhibitors 10215:antiretroviral drugs 9944:United Arab Emirates 9415:Circumcision and HIV 9372:City of Hope Patient 9132:structure and genome 8179:(6): 1114–1125.e10. 8136:10.1038/nrd.2017.243 7582:10.1038/mtna.2015.42 7462:on 21 September 2016 5571:(10189): 2428–2438. 4205:10.1128/AAC.01089-12 3692:10.1056/NEJMoa062360 2170:10.1128/AAC.00110-19 1379:zinc-finger nuclease 1194:Integrase inhibitors 1048:Immunologic response 485:Treatment guidelines 349:Combination therapy 262:Integrase inhibitors 257:Integrase inhibitors 27:antiretroviral drugs 10918:Experimental agents 10888:Lopinavir/ritonavir 10747:Abacavir/lamivudine 10721:Elsulfavirine (ESV) 10556:Emtricitabine (FTC) 10442:Fosamprenavir (FPV) 9492:AIDS Memorial Quilt 9304:HIV-positive people 8365:2011Sci...334.1097P 8359:(6059): 1097–1103. 8316:10.1038/nature12053 8308:2013Natur.496..469. 8030:2017Sci...355.1129H 8024:(6330): 1129–1130. 7857:10.1038/nature11286 7849:2012Natur.487..482A 7790:2010PLoSO...5.9390A 7514:The Washington Post 7229:. 454–455: 340–52. 6473:2007ToxAP.220...92B 6317:2012PLoSO...743803H 5946:2012Sci...336.1321S 5253:1998SciAm.279a.106B 5241:Scientific American 4074:2013InfGE..16..144P 3520:2011Sci...334.1628C 2646:on 14 January 2009. 2498:1996Sci...271.1582P 2465:on 8 September 2015 1623:Drug advertisements 1539:, begin to develop 1439:histone deacetylase 1435:memory CD4+ T cells 1325:electronic computer 1301:protease inhibitors 1172:Protease inhibitors 1167:Protease inhibitors 1119:can interfere with 975:Response to therapy 798:Special populations 765:protease inhibitors 711:integrase inhibitor 657:Baseline resistance 501:protease inhibitors 302:Protease inhibitors 297:Protease inhibitors 11215:Never to phase III 10361:Elvitegravir (EVG) 10356:Dolutegravir (DTG) 10351:Cabotegravir (CAB) 10069:Dominican Republic 9452:HIV/AIDS denialism 9377:Women and HIV/AIDS 9367:The London Patient 9234:Signs and symptoms 9142:CDC classification 7936:www.biosantech.org 7709:The New York Times 7429:UtrechtCentral.com 6937:Human Reproduction 6912:(15): 249, 255–6. 6387:20.500.12105/10623 6377:10.1093/jac/dkt206 5440:"Can't Pass It On" 4029:10.1093/cid/ciu003 3948:10.1093/jac/dkt238 3819:www.eacsociety.org 2419:Antiviral Research 1628:Direct-to-consumer 1341:medical literature 1231:Pregnancy planning 980:Virologic response 621:(WHO) guidelines. 507:. Later that year 445: 202:, and of NtRTIs – 109: 75:The United States 11237: 11236: 11184: 11183: 11030:Diarylpyrimidines 10733: 10732: 10729: 10728: 10709:Rilpivirine (RPV) 10693:diarylpyrimidines 10676:Delavirdine (DLV) 10571:Zalcitabine (ddC) 10528:nucleotide (NRTI) 10508: 10507: 10366:Raltegravir (RAL) 10346:Bictegravir (BIC) 10325:Fostemsavir (FTR) 10240:Lenacapavir (LEN) 10232:Capsid inhibitors 10177: 10176: 10155: 10154: 10077: 10076: 9558:The SING Campaign 9447:HIV/AIDS activism 9435:Cost of treatment 9357:Timothy Ray Brown 9352:World AIDS Museum 9030:Molecular Therapy 9004:"HIV/AIDS in NYC" 8302:(7446): 469–476. 7902:10.1111/imr.12083 7702:McNeil D (2014). 7270:New York Magazine 7054:978-0-309-03879-9 6986:10.1586/eri.10.94 6370:(10): 2349–2357. 6172:(9534): 489–504. 6112:Antiviral Therapy 5480:(Press release). 4344:(9441): 1236–43. 4173:978-0-443-06839-3 3654:978-92-4-150572-7 3465:(9903): 1515–24. 2948:(9221): 2147–52. 2345:978-0-955-16690-7 1960:"Guidelines: HIV" 1917:(9903): 1525–33. 1637:mountain climbing 1486:COVID-19 pandemic 1484:to deal with the 1453:Immune activation 1237:HIV and pregnancy 941:systematic review 887:Caesarian section 876:HIV and pregnancy 863:systematic review 763:(both latter are 605:Guideline sources 481:adults with HIV. 463:Adjunct treatment 386:natural selection 355:life cycle of HIV 11289: 11254: 11253: 11252: 11245: 11055:Hydroxycarbamide 10922: 10921: 10716:Doravirine (DOR) 10704:Etravirine (ETR) 10699:Dapivirine (DPV) 10671:Nevirapine (NVP) 10656: 10655: 10561:Lamivudine (3TC) 10551:Didanosine (ddI) 10522: 10521: 10495:Tipranavir (TPV) 10483:Atazanavir (ATV) 10467:Saquinavir (SQV) 10457:Nelfinavir (NFV) 10437:Amprenavir (APV) 10427: 10426: 10309:Ibalizumab (IBA) 10204: 10197: 10190: 10181: 10180: 10147:Papua New Guinea 9997: 9996: 9652: 9651: 9096: 9089: 9082: 9073: 9072: 9055: 9045: 9011: 9010: 9008: 9000: 8994: 8993: 8983: 8951: 8945: 8944: 8919:(9738): 355–66. 8908: 8899: 8898: 8870: 8861: 8860: 8850: 8818: 8809: 8808: 8798: 8774: 8765: 8764: 8762: 8760: 8755:on 17 March 2019 8751:. Archived from 8741: 8735: 8734: 8724: 8692: 8686: 8685: 8660:(5): 1392–1398. 8649: 8643: 8642: 8634: 8628: 8627: 8617: 8585: 8579: 8578: 8576: 8574: 8560: 8551: 8550: 8540: 8530: 8506: 8495: 8494: 8484: 8474: 8450: 8444: 8443: 8433: 8401: 8395: 8394: 8384: 8344: 8338: 8337: 8327: 8287: 8281: 8280: 8270: 8253:(7): 1093–1110. 8238: 8232: 8231: 8229: 8227: 8213: 8207: 8206: 8196: 8164: 8158: 8157: 8147: 8115: 8109: 8108: 8098: 8066: 8060: 8059: 8049: 8009: 8003: 8002: 7992: 7982: 7958: 7952: 7951: 7949: 7947: 7938:. Archived from 7928: 7922: 7921: 7885: 7879: 7878: 7868: 7828: 7822: 7821: 7811: 7801: 7769: 7763: 7762: 7752: 7720: 7714: 7713: 7699: 7693: 7692: 7682: 7650: 7644: 7643: 7633: 7601: 7595: 7594: 7584: 7560: 7554: 7553: 7551: 7549: 7532: 7526: 7525: 7523: 7521: 7504: 7498: 7497: 7495: 7493: 7478: 7472: 7471: 7469: 7467: 7461: 7454: 7446: 7440: 7439: 7437: 7435: 7420: 7414: 7413: 7411: 7409: 7394: 7388: 7385: 7379: 7378: 7368: 7336: 7330: 7329: 7311: 7287: 7281: 7280: 7278: 7276: 7261: 7255: 7254: 7224: 7215: 7204: 7203: 7193: 7184: 7183: 7181: 7179: 7168: 7159: 7158: 7140: 7116: 7110: 7109: 7073: 7067: 7066: 7036:Confronting AIDS 7030: 7024: 7023: 7022:. 21 March 1987. 7012: 7006: 7005: 6969: 6963: 6962: 6952: 6928: 6922: 6921: 6901: 6895: 6894: 6884: 6860: 6851: 6850: 6832: 6808: 6802: 6801: 6791: 6767: 6761: 6760: 6712: 6701: 6700: 6671: 6665: 6664: 6636: 6630: 6629: 6593: 6587: 6586: 6568: 6548: 6542: 6541: 6531: 6499: 6493: 6492: 6456: 6450: 6447: 6441: 6440: 6430: 6406: 6400: 6399: 6389: 6379: 6355: 6349: 6348: 6338: 6328: 6296: 6290: 6289: 6279: 6247: 6241: 6240: 6230: 6221:(44): 40847–57. 6206: 6200: 6199: 6189: 6157: 6146: 6145: 6127: 6103: 6097: 6096: 6086: 6069:(11): CD006495. 6054: 6048: 6047: 6045: 6043: 6033: 6027: 6026: 6016: 6006: 5982: 5976: 5975: 5965: 5940:(6086): 1321–5. 5925: 5919: 5918: 5908: 5876: 5870: 5869: 5840: 5834: 5833: 5823: 5791: 5785: 5784: 5755: 5749: 5748: 5746: 5744: 5723: 5717: 5707: 5705: 5703: 5697: 5686: 5680: 5679: 5669: 5659: 5632: 5626: 5625: 5623: 5621: 5607: 5601: 5600: 5590: 5580: 5556: 5545: 5544: 5519:(8): e438–e447. 5507: 5501: 5500: 5494: 5492: 5473: 5460: 5459: 5457: 5455: 5436: 5430: 5429: 5419: 5395: 5389: 5388: 5386: 5384: 5369: 5363: 5362: 5352: 5328: 5322: 5321: 5284: 5273: 5272: 5236: 5230: 5229: 5227: 5225: 5211: 5205: 5204: 5202: 5200: 5195:on 14 April 2014 5191:. Archived from 5180: 5174: 5173: 5163: 5131: 5125: 5124: 5122: 5120: 5115:on 16 April 2014 5101: 5095: 5094: 5092: 5090: 5079: 5073: 5072: 5070: 5068: 5053: 5047: 5046: 5036: 5004: 4998: 4997: 4987: 4955: 4946: 4945: 4935: 4918:(13): 1397–405. 4903: 4894: 4893: 4883: 4851: 4845: 4844: 4834: 4810: 4804: 4803: 4785: 4761: 4755: 4754: 4744: 4712: 4706: 4705: 4695: 4663: 4657: 4656: 4654: 4652: 4646: 4638: 4629: 4628: 4618: 4608: 4584: 4575: 4574: 4564: 4540: 4534: 4533: 4523: 4513: 4489: 4483: 4482: 4472: 4440: 4434: 4433: 4404: 4398: 4397: 4395: 4393: 4387: 4379: 4370: 4369: 4333: 4327: 4326: 4316: 4306: 4282: 4276: 4275: 4265: 4233: 4227: 4226: 4216: 4184: 4178: 4177: 4156: 4143: 4142: 4132: 4115:(12): CD004246. 4100: 4094: 4093: 4057: 4051: 4050: 4040: 4008: 4002: 4001: 3991: 3967: 3961: 3960: 3950: 3926: 3920: 3919: 3909: 3885: 3879: 3878: 3868: 3836: 3830: 3829: 3827: 3825: 3811: 3805: 3804: 3794: 3770: 3764: 3763: 3745: 3721: 3712: 3711: 3677: 3668: 3659: 3658: 3639: 3622: 3621: 3608: 3584: 3573: 3568: 3566: 3564: 3553: 3542: 3541: 3531: 3499: 3493: 3492: 3482: 3450: 3444: 3443: 3433: 3401: 3395: 3394: 3368: 3347: 3341: 3340: 3322: 3298: 3292: 3290: 3288: 3286: 3268: 3255: 3254: 3244: 3212: 3206: 3205: 3195: 3163: 3157: 3156: 3146: 3118: 3112: 3111: 3101: 3069: 3063: 3062: 3052: 3020: 3011: 3010: 2980: 2974: 2973: 2937: 2931: 2930: 2899: 2893: 2892: 2882: 2858: 2849: 2848: 2816: 2810: 2809: 2799: 2767: 2761: 2760: 2732: 2726: 2725: 2723: 2721: 2716:on 13 April 2014 2700: 2694: 2693: 2657: 2648: 2647: 2642:. Archived from 2621: 2615: 2614: 2604: 2580: 2574: 2573: 2545: 2536: 2535: 2509: 2492:(5255): 1582–6. 2481: 2475: 2474: 2472: 2470: 2449: 2443: 2442: 2414: 2405: 2404: 2394: 2365:Antiviral Agents 2356: 2350: 2349: 2331: 2322: 2321: 2311: 2279: 2270: 2269: 2233: 2227: 2226: 2198: 2192: 2191: 2181: 2149: 2143: 2142: 2106: 2083: 2082: 2072: 2062: 2038: 2023: 2022: 2015: 1980: 1979: 1977: 1975: 1970:on 26 March 2005 1966:. Archived from 1956: 1945: 1944: 1934: 1902: 1896: 1895: 1885: 1858: 1852: 1851: 1811: 1802: 1801: 1791: 1767: 1758: 1757: 1755: 1731: 1678:health disparity 1612:Scripps Research 1537:white blood cell 1424:Viral reservoirs 1329:digital computer 1215:mucous membranes 1028:Anthony S. Fauci 939:treatment. In a 810:viral reservoirs 682:("backbone")+ a 421:standard of care 125:Entry inhibitors 120:Entry inhibitors 89:viral resistance 11297: 11296: 11292: 11291: 11290: 11288: 11287: 11286: 11262: 11261: 11260: 11250: 11248: 11240: 11238: 11233: 11232: 11220: 11205:Clinical trials 11180: 11131:Dexelvucitabine 11099: 11090:Tre recombinase 10993: 10975: 10957: 10953:Tat antagonists 10939: 10913: 10892: 10725: 10680: 10666:Efavirenz (EFV) 10645: 10637: 10566:Stavudine (d4T) 10527: 10515: 10504: 10489:Darunavir (DRV) 10471: 10462:Ritonavir (RTV) 10452:Lopinavir (LPV) 10447:Indinavir (IDV) 10416: 10408: 10380: 10338: 10330: 10284:Maraviroc (MVC) 10252: 10244: 10226: 10211:Antiviral drugs 10208: 10178: 10173: 10151: 10125: 10073: 10045: 9986: 9958: 9904:Myanmar (Burma) 9793: 9641: 9627:Day Without Art 9573:The Global Fund 9501: 9430:Economic impact 9386: 9318: 9222: 9174:pathophysiology 9110: 9100: 9062: 9020: 9018:Further reading 9015: 9014: 9006: 9002: 9001: 8997: 8966:(3): CD010806. 8952: 8948: 8909: 8902: 8871: 8864: 8819: 8812: 8783:The Lancet. HIV 8775: 8768: 8758: 8756: 8743: 8742: 8738: 8693: 8689: 8650: 8646: 8635: 8631: 8586: 8582: 8572: 8570: 8568:www.scripps.edu 8562: 8561: 8554: 8507: 8498: 8451: 8447: 8402: 8398: 8345: 8341: 8288: 8284: 8239: 8235: 8225: 8223: 8221:hivinfo.nih.gov 8215: 8214: 8210: 8165: 8161: 8116: 8112: 8067: 8063: 8010: 8006: 7959: 7955: 7945: 7943: 7930: 7929: 7925: 7886: 7882: 7843:(7408): 482–5. 7829: 7825: 7770: 7766: 7735:(19): 1828–35. 7721: 7717: 7700: 7696: 7671:10.1038/nm.1972 7659:Nature Medicine 7651: 7647: 7602: 7598: 7561: 7557: 7547: 7545: 7533: 7529: 7519: 7517: 7505: 7501: 7491: 7489: 7479: 7475: 7465: 7463: 7459: 7452: 7448: 7447: 7443: 7433: 7431: 7421: 7417: 7407: 7405: 7395: 7391: 7386: 7382: 7337: 7333: 7288: 7284: 7274: 7272: 7262: 7258: 7222: 7216: 7207: 7194: 7187: 7177: 7175: 7170: 7169: 7162: 7117: 7113: 7074: 7070: 7055: 7031: 7027: 7014: 7013: 7009: 6980:(10): 1163–75. 6970: 6966: 6929: 6925: 6902: 6898: 6861: 6854: 6809: 6805: 6782:(21): 1485–90. 6768: 6764: 6713: 6704: 6672: 6668: 6637: 6633: 6594: 6590: 6549: 6545: 6500: 6496: 6457: 6453: 6448: 6444: 6407: 6403: 6356: 6352: 6297: 6293: 6248: 6244: 6207: 6203: 6158: 6149: 6104: 6100: 6055: 6051: 6041: 6039: 6035: 6034: 6030: 5997:(6): e1004198. 5983: 5979: 5926: 5922: 5877: 5873: 5841: 5837: 5806:(12): 1867–76. 5792: 5788: 5756: 5752: 5742: 5740: 5724: 5720: 5701: 5699: 5695: 5687: 5683: 5633: 5629: 5619: 5617: 5608: 5604: 5557: 5548: 5513:The Lancet. HIV 5508: 5504: 5490: 5488: 5474: 5463: 5453: 5451: 5438: 5437: 5433: 5404:The Lancet. HIV 5396: 5392: 5382: 5380: 5370: 5366: 5329: 5325: 5285: 5276: 5237: 5233: 5223: 5221: 5213: 5212: 5208: 5198: 5196: 5181: 5177: 5146:(18): 1715–25. 5132: 5128: 5118: 5116: 5103: 5102: 5098: 5088: 5086: 5081: 5080: 5076: 5066: 5064: 5055: 5054: 5050: 5005: 5001: 4970:(1): CD008525. 4956: 4949: 4904: 4897: 4866:(16): 2469–79. 4852: 4848: 4811: 4807: 4762: 4758: 4727:(8): 1193–202. 4713: 4709: 4664: 4660: 4650: 4648: 4644: 4640: 4639: 4632: 4585: 4578: 4541: 4537: 4490: 4486: 4441: 4437: 4405: 4401: 4391: 4389: 4385: 4381: 4380: 4373: 4334: 4330: 4283: 4279: 4234: 4230: 4199:(10): 5409–13. 4185: 4181: 4174: 4158: 4157: 4146: 4101: 4097: 4058: 4054: 4009: 4005: 3968: 3964: 3941:(11): 2626–31. 3927: 3923: 3886: 3882: 3837: 3833: 3823: 3821: 3813: 3812: 3808: 3771: 3767: 3736:(14): 1957–63. 3722: 3715: 3686:(22): 2283–96. 3675: 3669: 3662: 3655: 3641: 3640: 3625: 3585: 3576: 3562: 3560: 3555: 3554: 3545: 3500: 3496: 3451: 3447: 3402: 3398: 3366:10.1.1.567.3563 3348: 3344: 3299: 3295: 3284: 3282: 3270: 3269: 3258: 3227:(16): 2143–53. 3213: 3209: 3164: 3160: 3119: 3115: 3070: 3066: 3035:(18): 1815–26. 3021: 3014: 3007: 2981: 2977: 2938: 2934: 2900: 2896: 2859: 2852: 2817: 2813: 2782:(5): CD009818. 2768: 2764: 2733: 2729: 2719: 2717: 2702: 2701: 2697: 2658: 2651: 2622: 2618: 2581: 2577: 2546: 2539: 2482: 2478: 2468: 2466: 2451: 2450: 2446: 2415: 2408: 2383: 2357: 2353: 2346: 2332: 2325: 2280: 2273: 2234: 2230: 2199: 2195: 2150: 2146: 2107: 2086: 2039: 2026: 2016: 1983: 1973: 1971: 1958: 1957: 1948: 1903: 1899: 1859: 1855: 1812: 1805: 1782:(14): 1933–42. 1768: 1761: 1732: 1728: 1723: 1691: 1670: 1668:Food insecurity 1654: 1646:Freddie Mercury 1625: 1583:T-cell-mediated 1471: 1455: 1426: 1364:The so-called " 1362: 1353: 1345:regularly cited 1274: 1239: 1233: 1211: 1205: 1196: 1169: 1153: 1125:lactic acidosis 1113: 1105: 1103:Adverse effects 1090: 1082:salvage therapy 1065: 1063:Salvage therapy 1050: 982: 977: 954: 932: 899: 882: 874:Main articles: 872: 826: 805: 803:Acute infection 800: 776:cytochrome p450 676: 666:+ lamivudine + 659: 627: 607: 545: 531:(Rekambys) and 492: 487: 465: 351: 299: 259: 223:allosteric site 216: 161: 122: 101: 49:, and prevents 17: 12: 11: 5: 11295: 11285: 11284: 11279: 11274: 11259: 11258: 11235: 11234: 11219: 11218: 11217: 11216: 11213: 11202: 11196: 11190: 11189: 11186: 11185: 11182: 11181: 11179: 11178: 11173: 11168: 11163: 11158: 11153: 11148: 11143: 11138: 11133: 11128: 11123: 11118: 11113: 11107: 11105: 11101: 11100: 11098: 11097: 11092: 11087: 11082: 11077: 11072: 11067: 11062: 11057: 11052: 11047: 11042: 11037: 11032: 11027: 11022: 11017: 11012: 11007: 11001: 10999: 10995: 10994: 10992: 10991: 10985: 10983: 10977: 10976: 10974: 10973: 10967: 10965: 10959: 10958: 10956: 10955: 10949: 10947: 10941: 10940: 10938: 10937: 10930: 10928: 10919: 10915: 10914: 10912: 10911: 10906: 10904:Cobicistat (c) 10900: 10898: 10894: 10893: 10891: 10890: 10885: 10880: 10875: 10870: 10865: 10860: 10855: 10850: 10845: 10840: 10835: 10830: 10825: 10820: 10815: 10810: 10804: 10798: 10792: 10787: 10781: 10776: 10771: 10765: 10760: 10755: 10749: 10743: 10741: 10735: 10734: 10731: 10730: 10727: 10726: 10724: 10723: 10718: 10713: 10712: 10711: 10706: 10701: 10688: 10686: 10682: 10681: 10679: 10678: 10673: 10668: 10662: 10660: 10653: 10639: 10638: 10636: 10635: 10630: 10614: 10613: 10608: 10603: 10598: 10593: 10588: 10583: 10578: 10573: 10568: 10563: 10558: 10553: 10548: 10546:Abacavir (ABC) 10532: 10530: 10526:Nucleoside and 10519: 10510: 10509: 10506: 10505: 10503: 10502: 10497: 10492: 10486: 10479: 10477: 10473: 10472: 10470: 10469: 10464: 10459: 10454: 10449: 10444: 10439: 10433: 10431: 10424: 10410: 10409: 10407: 10406: 10401: 10396: 10390: 10388: 10382: 10381: 10379: 10378: 10373: 10368: 10363: 10358: 10353: 10348: 10342: 10340: 10332: 10331: 10329: 10328: 10316: 10300: 10286: 10275: 10262: 10260: 10246: 10245: 10243: 10242: 10236: 10234: 10228: 10227: 10207: 10206: 10199: 10192: 10184: 10175: 10174: 10172: 10171: 10166: 10160: 10157: 10156: 10153: 10152: 10150: 10149: 10144: 10139: 10133: 10131: 10127: 10126: 10124: 10123: 10118: 10113: 10108: 10103: 10098: 10093: 10087: 10085: 10079: 10078: 10075: 10074: 10072: 10071: 10066: 10061: 10055: 10053: 10047: 10046: 10044: 10043: 10042: 10041: 10031: 10026: 10021: 10016: 10011: 10006: 10000: 9994: 9988: 9987: 9985: 9984: 9979: 9974: 9972:United Kingdom 9968: 9966: 9960: 9959: 9957: 9956: 9951: 9946: 9941: 9936: 9931: 9926: 9921: 9916: 9911: 9906: 9901: 9896: 9891: 9886: 9881: 9876: 9871: 9866: 9861: 9856: 9851: 9850: 9849: 9839: 9834: 9829: 9824: 9819: 9814: 9809: 9803: 9801: 9795: 9794: 9792: 9791: 9786: 9781: 9776: 9771: 9766: 9761: 9756: 9751: 9746: 9741: 9736: 9731: 9726: 9721: 9716: 9711: 9706: 9701: 9696: 9691: 9686: 9681: 9676: 9671: 9666: 9660: 9658: 9649: 9643: 9642: 9640: 9639: 9634: 9629: 9624: 9619: 9618: 9617: 9612: 9605: 9600: 9590: 9585: 9583:YAA/Youthforce 9580: 9578:World AIDS Day 9575: 9570: 9565: 9560: 9555: 9550: 9545: 9540: 9535: 9530: 9525: 9520: 9515: 9509: 9507: 9503: 9502: 9500: 9499: 9494: 9489: 9484: 9479: 9474: 9469: 9464: 9459: 9454: 9449: 9444: 9439: 9438: 9437: 9427: 9422: 9417: 9412: 9411: 9410: 9400: 9394: 9392: 9388: 9387: 9385: 9384: 9379: 9374: 9369: 9364: 9362:Berlin Patient 9359: 9354: 9349: 9344: 9343: 9342: 9332: 9326: 9324: 9320: 9319: 9317: 9316: 9311: 9306: 9301: 9296: 9291: 9286: 9281: 9279:Superinfection 9276: 9271: 9266: 9261: 9259:Cardiomyopathy 9256: 9251: 9246: 9241: 9236: 9230: 9228: 9224: 9223: 9221: 9220: 9215: 9214: 9213: 9211:Teens / Adults 9208: 9198: 9197: 9196: 9191: 9186: 9181: 9176: 9171: 9166: 9156: 9155: 9154: 9149: 9144: 9139: 9134: 9129: 9118: 9116: 9112: 9111: 9099: 9098: 9091: 9084: 9076: 9070: 9069: 9061: 9060:External links 9058: 9057: 9056: 9019: 9016: 9013: 9012: 8995: 8946: 8900: 8862: 8810: 8766: 8745:"Constitution" 8736: 8707:(7295): 1143. 8687: 8654:Health Affairs 8644: 8629: 8600:(3): 499–514. 8580: 8552: 8496: 8445: 8416:(1): 635–659. 8396: 8339: 8282: 8233: 8208: 8159: 8130:(4): 261–279. 8110: 8081:(4): 582–608. 8061: 8004: 7953: 7942:on 1 June 2016 7923: 7880: 7823: 7764: 7715: 7694: 7665:(8): 893–900. 7645: 7616:(4): 363–365. 7596: 7555: 7527: 7499: 7473: 7441: 7415: 7389: 7380: 7351:(10): 901–10. 7331: 7282: 7256: 7205: 7185: 7160: 7131:(11): 725–33. 7111: 7068: 7053: 7025: 7020:New York Times 7007: 6964: 6923: 6896: 6852: 6803: 6762: 6733:10.1086/672271 6702: 6683:(12): 1451–8. 6666: 6631: 6588: 6543: 6494: 6451: 6442: 6421:(4): 213–220. 6401: 6350: 6291: 6242: 6201: 6147: 6098: 6049: 6028: 5991:PLOS Pathogens 5977: 5920: 5891:(2): 391–405. 5871: 5858:10.1086/695852 5835: 5786: 5750: 5730:(3 May 2019). 5718: 5681: 5627: 5602: 5546: 5502: 5461: 5431: 5390: 5364: 5343:(7): 797–804. 5323: 5296:(4): 387–402. 5274: 5231: 5206: 5175: 5126: 5096: 5074: 5063:on 20 May 2006 5048: 5019:(9): 1035–46. 4999: 4947: 4895: 4846: 4805: 4756: 4707: 4684:10.1086/374273 4658: 4630: 4606:10.1086/427287 4576: 4555:(6): 394–402. 4535: 4484: 4455:(25): 2380–9. 4435: 4416:(10): 989–96. 4399: 4371: 4328: 4304:10.1086/590501 4277: 4228: 4179: 4172: 4144: 4095: 4052: 4003: 3962: 3921: 3907:10.1086/427212 3880: 3851:(7529): 1368. 3831: 3806: 3765: 3713: 3660: 3653: 3623: 3574: 3543: 3514:(6063): 1628. 3494: 3445: 3416:(6): 493–505. 3396: 3342: 3293: 3256: 3207: 3184:10.1086/597093 3158: 3113: 3084:(9): 795–807. 3064: 3012: 3005: 2975: 2932: 2894: 2850: 2811: 2762: 2727: 2695: 2649: 2616: 2575: 2550:Virus Research 2537: 2507:10.1.1.34.7762 2476: 2444: 2406: 2381: 2351: 2344: 2338:. Mediscript. 2323: 2271: 2228: 2209:(7): 1228–50. 2193: 2144: 2084: 2024: 1981: 1946: 1897: 1853: 1826:(5): 451–452. 1803: 1759: 1746:(3): 192–194. 1725: 1724: 1722: 1719: 1718: 1717: 1712: 1707: 1702: 1697: 1690: 1687: 1669: 1666: 1653: 1650: 1624: 1621: 1545:memory B cells 1517:viral envelope 1470: 1467: 1454: 1451: 1425: 1422: 1410:London Patient 1391:Berlin patient 1366:Berlin patient 1361: 1358: 1352: 1349: 1273: 1270: 1232: 1229: 1204: 1201: 1195: 1192: 1168: 1165: 1152: 1149: 1112: 1109: 1104: 1101: 1089: 1086: 1064: 1061: 1049: 1046: 981: 978: 976: 973: 972: 971: 968: 964: 961: 953: 950: 931: 928: 898: 895: 871: 870:Pregnant women 868: 856: 855: 845: 844: 825: 822: 804: 801: 799: 796: 795: 794: 769: 768: 753: 738: 721: 714: 675: 672: 658: 655: 654: 653: 646: 645: 641: 638: 626: 623: 606: 603: 561:serodiscordant 554:clinical trial 544: 541: 491: 488: 486: 483: 464: 461: 350: 347: 298: 295: 258: 255: 215: 212: 160: 157: 121: 118: 100: 97: 55:serodiscordant 15: 9: 6: 4: 3: 2: 11294: 11283: 11280: 11278: 11275: 11273: 11270: 11269: 11267: 11257: 11247: 11246: 11243: 11230: 11227: 11224: 11214: 11212: 11209: 11208: 11206: 11203: 11200: 11197: 11195: 11192: 11191: 11187: 11177: 11174: 11172: 11169: 11167: 11164: 11162: 11159: 11157: 11154: 11152: 11149: 11147: 11144: 11142: 11139: 11137: 11134: 11132: 11129: 11127: 11124: 11122: 11119: 11117: 11114: 11112: 11109: 11108: 11106: 11104:Failed agents 11102: 11096: 11093: 11091: 11088: 11086: 11083: 11081: 11078: 11076: 11073: 11071: 11068: 11066: 11063: 11061: 11058: 11056: 11053: 11051: 11048: 11046: 11043: 11041: 11038: 11036: 11033: 11031: 11028: 11026: 11023: 11021: 11018: 11016: 11013: 11011: 11008: 11006: 11003: 11002: 11000: 10996: 10990: 10987: 10986: 10984: 10982: 10978: 10972: 10971:Trichosanthin 10969: 10968: 10966: 10964: 10960: 10954: 10951: 10950: 10948: 10946: 10942: 10935: 10932: 10931: 10929: 10927: 10923: 10920: 10916: 10910: 10909:Ritonavir (r) 10907: 10905: 10902: 10901: 10899: 10895: 10889: 10886: 10884: 10881: 10879: 10876: 10874: 10871: 10869: 10866: 10864: 10861: 10859: 10856: 10854: 10851: 10849: 10846: 10844: 10841: 10839: 10836: 10834: 10831: 10829: 10826: 10824: 10821: 10819: 10816: 10814: 10811: 10808: 10805: 10802: 10799: 10796: 10793: 10791: 10788: 10785: 10782: 10780: 10777: 10775: 10772: 10769: 10766: 10764: 10761: 10759: 10756: 10753: 10750: 10748: 10745: 10744: 10742: 10740: 10736: 10722: 10719: 10717: 10714: 10710: 10707: 10705: 10702: 10700: 10697: 10696: 10695: 10694: 10690: 10689: 10687: 10683: 10677: 10674: 10672: 10669: 10667: 10664: 10663: 10661: 10657: 10654: 10652: 10650: 10644: 10640: 10634: 10631: 10629: 10626: 10624: 10620: 10616: 10615: 10612: 10609: 10607: 10604: 10602: 10599: 10597: 10594: 10592: 10589: 10587: 10584: 10582: 10579: 10577: 10574: 10572: 10569: 10567: 10564: 10562: 10559: 10557: 10554: 10552: 10549: 10547: 10544: 10542: 10538: 10534: 10533: 10531: 10529: 10523: 10520: 10517: 10511: 10501: 10498: 10496: 10493: 10490: 10487: 10484: 10481: 10480: 10478: 10474: 10468: 10465: 10463: 10460: 10458: 10455: 10453: 10450: 10448: 10445: 10443: 10440: 10438: 10435: 10434: 10432: 10428: 10425: 10423: 10421: 10415: 10411: 10405: 10402: 10400: 10397: 10395: 10392: 10391: 10389: 10387: 10383: 10377: 10374: 10372: 10369: 10367: 10364: 10362: 10359: 10357: 10354: 10352: 10349: 10347: 10344: 10343: 10341: 10337: 10333: 10326: 10322: 10321: 10317: 10314: 10310: 10306: 10305: 10301: 10298: 10294: 10290: 10287: 10285: 10281: 10280: 10276: 10273: 10269: 10268: 10264: 10263: 10261: 10259: 10257: 10251: 10247: 10241: 10238: 10237: 10235: 10233: 10229: 10224: 10220: 10217:used against 10216: 10212: 10205: 10200: 10198: 10193: 10191: 10186: 10185: 10182: 10170: 10167: 10165: 10162: 10161: 10158: 10148: 10145: 10143: 10140: 10138: 10135: 10134: 10132: 10128: 10122: 10119: 10117: 10114: 10112: 10109: 10107: 10104: 10102: 10099: 10097: 10094: 10092: 10089: 10088: 10086: 10084: 10083:South America 10080: 10070: 10067: 10065: 10062: 10060: 10057: 10056: 10054: 10052: 10048: 10040: 10039:New York City 10037: 10036: 10035: 10034:United States 10032: 10030: 10027: 10025: 10022: 10020: 10017: 10015: 10012: 10010: 10007: 10005: 10002: 10001: 9998: 9995: 9993: 9992:North America 9989: 9983: 9980: 9978: 9975: 9973: 9970: 9969: 9967: 9965: 9961: 9955: 9952: 9950: 9947: 9945: 9942: 9940: 9937: 9935: 9932: 9930: 9927: 9925: 9922: 9920: 9917: 9915: 9912: 9910: 9907: 9905: 9902: 9900: 9897: 9895: 9892: 9890: 9887: 9885: 9882: 9880: 9877: 9875: 9872: 9870: 9867: 9865: 9862: 9860: 9857: 9855: 9852: 9848: 9845: 9844: 9843: 9840: 9838: 9835: 9833: 9830: 9828: 9825: 9823: 9820: 9818: 9815: 9813: 9810: 9808: 9805: 9804: 9802: 9800: 9796: 9790: 9787: 9785: 9782: 9780: 9777: 9775: 9772: 9770: 9767: 9765: 9762: 9760: 9757: 9755: 9752: 9750: 9747: 9745: 9742: 9740: 9737: 9735: 9732: 9730: 9727: 9725: 9722: 9720: 9717: 9715: 9712: 9710: 9707: 9705: 9702: 9700: 9697: 9695: 9692: 9690: 9687: 9685: 9682: 9680: 9677: 9675: 9672: 9670: 9667: 9665: 9662: 9661: 9659: 9657: 9653: 9650: 9648: 9644: 9638: 9635: 9633: 9630: 9628: 9625: 9623: 9620: 9616: 9613: 9611: 9610: 9606: 9604: 9601: 9599: 9596: 9595: 9594: 9591: 9589: 9586: 9584: 9581: 9579: 9576: 9574: 9571: 9569: 9566: 9564: 9561: 9559: 9556: 9554: 9551: 9549: 9546: 9544: 9541: 9539: 9536: 9534: 9531: 9529: 9526: 9524: 9521: 9519: 9516: 9514: 9511: 9510: 9508: 9504: 9498: 9495: 9493: 9490: 9488: 9485: 9483: 9480: 9478: 9475: 9473: 9470: 9468: 9467:Sex education 9465: 9463: 9460: 9458: 9455: 9453: 9450: 9448: 9445: 9443: 9440: 9436: 9433: 9432: 9431: 9428: 9426: 9423: 9421: 9418: 9416: 9413: 9409: 9406: 9405: 9404: 9401: 9399: 9396: 9395: 9393: 9389: 9383: 9380: 9378: 9375: 9373: 9370: 9368: 9365: 9363: 9360: 9358: 9355: 9353: 9350: 9348: 9345: 9341: 9338: 9337: 9336: 9333: 9331: 9328: 9327: 9325: 9321: 9315: 9312: 9310: 9307: 9305: 9302: 9300: 9297: 9295: 9292: 9290: 9287: 9285: 9282: 9280: 9277: 9275: 9272: 9270: 9267: 9265: 9262: 9260: 9257: 9255: 9252: 9250: 9249:Lipodystrophy 9247: 9245: 9242: 9240: 9237: 9235: 9232: 9231: 9229: 9225: 9219: 9216: 9212: 9209: 9207: 9204: 9203: 9202: 9199: 9195: 9192: 9190: 9187: 9185: 9182: 9180: 9177: 9175: 9172: 9170: 9167: 9165: 9162: 9161: 9160: 9157: 9153: 9150: 9148: 9145: 9143: 9140: 9138: 9135: 9133: 9130: 9128: 9125: 9124: 9123: 9120: 9119: 9117: 9113: 9108: 9104: 9097: 9092: 9090: 9085: 9083: 9078: 9077: 9074: 9067: 9064: 9063: 9053: 9049: 9044: 9039: 9036:(6): 823–42. 9035: 9031: 9027: 9022: 9021: 9005: 8999: 8991: 8987: 8982: 8977: 8973: 8969: 8965: 8961: 8957: 8950: 8942: 8938: 8934: 8930: 8926: 8922: 8918: 8914: 8907: 8905: 8896: 8892: 8888: 8884: 8881:(2): 245–61. 8880: 8876: 8869: 8867: 8858: 8854: 8849: 8844: 8840: 8836: 8833:(7): 651–72. 8832: 8828: 8824: 8817: 8815: 8806: 8802: 8797: 8792: 8789:(1): e32-40. 8788: 8784: 8780: 8773: 8771: 8754: 8750: 8746: 8740: 8732: 8728: 8723: 8718: 8714: 8710: 8706: 8702: 8698: 8691: 8683: 8679: 8675: 8671: 8667: 8663: 8659: 8655: 8648: 8640: 8633: 8625: 8621: 8616: 8611: 8607: 8603: 8599: 8595: 8591: 8584: 8569: 8565: 8559: 8557: 8548: 8544: 8539: 8534: 8529: 8524: 8520: 8516: 8512: 8505: 8503: 8501: 8492: 8488: 8483: 8478: 8473: 8468: 8464: 8460: 8459:Retrovirology 8456: 8449: 8441: 8437: 8432: 8427: 8423: 8419: 8415: 8411: 8407: 8400: 8392: 8388: 8383: 8378: 8374: 8370: 8366: 8362: 8358: 8354: 8350: 8343: 8335: 8331: 8326: 8321: 8317: 8313: 8309: 8305: 8301: 8297: 8293: 8286: 8278: 8274: 8269: 8264: 8260: 8256: 8252: 8248: 8244: 8237: 8222: 8218: 8212: 8204: 8200: 8195: 8190: 8186: 8182: 8178: 8174: 8170: 8163: 8155: 8151: 8146: 8141: 8137: 8133: 8129: 8125: 8121: 8114: 8106: 8102: 8097: 8092: 8088: 8084: 8080: 8076: 8072: 8065: 8057: 8053: 8048: 8043: 8039: 8035: 8031: 8027: 8023: 8019: 8015: 8008: 8000: 7996: 7991: 7986: 7981: 7976: 7972: 7968: 7967:Retrovirology 7964: 7957: 7941: 7937: 7933: 7927: 7919: 7915: 7911: 7907: 7903: 7899: 7896:(1): 355–71. 7895: 7891: 7884: 7876: 7872: 7867: 7862: 7858: 7854: 7850: 7846: 7842: 7838: 7834: 7827: 7819: 7815: 7810: 7805: 7800: 7795: 7791: 7787: 7783: 7779: 7775: 7768: 7760: 7756: 7751: 7746: 7742: 7738: 7734: 7730: 7726: 7719: 7711: 7710: 7705: 7698: 7690: 7686: 7681: 7676: 7672: 7668: 7664: 7660: 7656: 7649: 7641: 7637: 7632: 7627: 7623: 7619: 7615: 7611: 7607: 7600: 7592: 7588: 7583: 7578: 7574: 7570: 7566: 7559: 7544: 7543: 7538: 7531: 7516: 7515: 7510: 7503: 7488: 7484: 7477: 7458: 7451: 7445: 7430: 7426: 7419: 7404: 7400: 7393: 7384: 7376: 7372: 7367: 7362: 7358: 7354: 7350: 7346: 7342: 7335: 7327: 7323: 7319: 7315: 7310: 7305: 7301: 7297: 7293: 7286: 7271: 7267: 7260: 7252: 7248: 7244: 7240: 7236: 7232: 7228: 7221: 7214: 7212: 7210: 7201: 7200: 7192: 7190: 7173: 7167: 7165: 7156: 7152: 7148: 7144: 7139: 7134: 7130: 7126: 7122: 7115: 7107: 7103: 7099: 7095: 7091: 7087: 7084:(7): 633–42. 7083: 7079: 7072: 7064: 7060: 7056: 7050: 7046: 7042: 7038: 7037: 7029: 7021: 7017: 7011: 7003: 6999: 6995: 6991: 6987: 6983: 6979: 6975: 6968: 6960: 6956: 6951: 6946: 6942: 6938: 6934: 6927: 6919: 6915: 6911: 6907: 6900: 6892: 6888: 6883: 6878: 6875:(2): 136–50. 6874: 6870: 6866: 6859: 6857: 6848: 6844: 6840: 6836: 6831: 6826: 6823:(4): 345–52. 6822: 6818: 6814: 6807: 6799: 6795: 6790: 6785: 6781: 6777: 6773: 6766: 6758: 6754: 6750: 6746: 6742: 6738: 6734: 6730: 6727:(9): 875–92. 6726: 6722: 6718: 6711: 6709: 6707: 6698: 6694: 6690: 6686: 6682: 6678: 6670: 6662: 6658: 6654: 6650: 6646: 6642: 6635: 6627: 6623: 6619: 6615: 6611: 6607: 6603: 6599: 6592: 6584: 6580: 6576: 6572: 6567: 6562: 6558: 6554: 6547: 6539: 6535: 6530: 6525: 6521: 6517: 6513: 6509: 6505: 6498: 6490: 6486: 6482: 6478: 6474: 6470: 6467:(1): 92–107. 6466: 6462: 6455: 6446: 6438: 6434: 6429: 6424: 6420: 6416: 6412: 6405: 6397: 6393: 6388: 6383: 6378: 6373: 6369: 6365: 6361: 6354: 6346: 6342: 6337: 6332: 6327: 6322: 6318: 6314: 6311:(8): e43803. 6310: 6306: 6302: 6295: 6287: 6283: 6278: 6273: 6269: 6265: 6262:(3): 716–23. 6261: 6257: 6253: 6246: 6238: 6234: 6229: 6224: 6220: 6216: 6212: 6205: 6197: 6193: 6188: 6183: 6179: 6175: 6171: 6167: 6163: 6156: 6154: 6152: 6143: 6139: 6135: 6131: 6126: 6121: 6117: 6113: 6109: 6102: 6094: 6090: 6085: 6080: 6076: 6072: 6068: 6064: 6060: 6053: 6038: 6032: 6024: 6020: 6015: 6010: 6005: 6000: 5996: 5992: 5988: 5981: 5973: 5969: 5964: 5959: 5955: 5951: 5947: 5943: 5939: 5935: 5931: 5924: 5916: 5912: 5907: 5902: 5898: 5894: 5890: 5886: 5882: 5875: 5867: 5863: 5859: 5855: 5852:(3): 328–37. 5851: 5847: 5839: 5831: 5827: 5822: 5817: 5813: 5809: 5805: 5801: 5797: 5790: 5782: 5778: 5774: 5770: 5766: 5762: 5754: 5739: 5738: 5733: 5729: 5722: 5715: 5714:NAM / AIDSmap 5711: 5694: 5693: 5685: 5677: 5673: 5668: 5663: 5658: 5653: 5649: 5645: 5641: 5637: 5631: 5615: 5614: 5606: 5598: 5594: 5589: 5584: 5579: 5574: 5570: 5566: 5562: 5555: 5553: 5551: 5542: 5538: 5534: 5530: 5526: 5522: 5518: 5514: 5506: 5499: 5487: 5483: 5479: 5472: 5470: 5468: 5466: 5449: 5445: 5441: 5435: 5427: 5423: 5418: 5413: 5409: 5405: 5402:. Editorial. 5401: 5394: 5379: 5375: 5368: 5360: 5356: 5351: 5346: 5342: 5338: 5334: 5327: 5319: 5315: 5311: 5307: 5303: 5299: 5295: 5291: 5283: 5281: 5279: 5270: 5266: 5262: 5258: 5254: 5250: 5246: 5242: 5235: 5220: 5216: 5210: 5194: 5190: 5186: 5179: 5171: 5167: 5162: 5157: 5153: 5149: 5145: 5141: 5137: 5130: 5114: 5110: 5109:The Raw Story 5106: 5100: 5084: 5078: 5062: 5058: 5052: 5044: 5040: 5035: 5030: 5026: 5022: 5018: 5014: 5010: 5003: 4995: 4991: 4986: 4981: 4977: 4973: 4969: 4965: 4961: 4954: 4952: 4943: 4939: 4934: 4929: 4925: 4921: 4917: 4913: 4909: 4902: 4900: 4891: 4887: 4882: 4877: 4873: 4869: 4865: 4861: 4857: 4850: 4842: 4838: 4833: 4828: 4825:(7): 684–91. 4824: 4820: 4816: 4809: 4801: 4797: 4793: 4789: 4784: 4779: 4775: 4771: 4767: 4760: 4752: 4748: 4743: 4738: 4734: 4730: 4726: 4722: 4718: 4711: 4703: 4699: 4694: 4689: 4685: 4681: 4677: 4673: 4669: 4662: 4643: 4637: 4635: 4626: 4622: 4617: 4616:11577/2435265 4612: 4607: 4602: 4599:(3): 458–65. 4598: 4594: 4590: 4583: 4581: 4572: 4568: 4563: 4558: 4554: 4550: 4546: 4539: 4531: 4527: 4522: 4517: 4512: 4507: 4503: 4499: 4495: 4488: 4480: 4476: 4471: 4466: 4462: 4458: 4454: 4450: 4446: 4439: 4431: 4427: 4423: 4419: 4415: 4411: 4403: 4384: 4378: 4376: 4367: 4363: 4359: 4355: 4351: 4347: 4343: 4339: 4332: 4324: 4320: 4315: 4310: 4305: 4300: 4297:(5): 687–93. 4296: 4292: 4288: 4281: 4273: 4269: 4264: 4259: 4255: 4251: 4248:(3): 207–17. 4247: 4243: 4239: 4232: 4224: 4220: 4215: 4210: 4206: 4202: 4198: 4194: 4190: 4183: 4175: 4169: 4165: 4161: 4155: 4153: 4151: 4149: 4140: 4136: 4131: 4126: 4122: 4118: 4114: 4110: 4106: 4099: 4091: 4087: 4083: 4079: 4075: 4071: 4067: 4063: 4056: 4048: 4044: 4039: 4034: 4030: 4026: 4023:(6): 865–72. 4022: 4018: 4014: 4007: 3999: 3995: 3990: 3985: 3981: 3977: 3973: 3966: 3958: 3954: 3949: 3944: 3940: 3936: 3932: 3925: 3917: 3913: 3908: 3903: 3900:(3): 468–74. 3899: 3895: 3891: 3884: 3876: 3872: 3867: 3862: 3858: 3854: 3850: 3846: 3842: 3835: 3820: 3816: 3810: 3802: 3798: 3793: 3788: 3785:(4): 410–25. 3784: 3780: 3776: 3769: 3761: 3757: 3753: 3749: 3744: 3739: 3735: 3731: 3727: 3720: 3718: 3709: 3705: 3701: 3697: 3693: 3689: 3685: 3681: 3674: 3667: 3665: 3656: 3650: 3646: 3645: 3638: 3636: 3634: 3632: 3630: 3628: 3620: 3616: 3612: 3607: 3602: 3599:(2): 171–81. 3598: 3594: 3590: 3583: 3581: 3579: 3571: 3558: 3552: 3550: 3548: 3539: 3535: 3530: 3525: 3521: 3517: 3513: 3509: 3505: 3498: 3490: 3486: 3481: 3476: 3472: 3468: 3464: 3460: 3456: 3449: 3441: 3437: 3432: 3427: 3423: 3419: 3415: 3411: 3407: 3400: 3392: 3388: 3384: 3380: 3376: 3372: 3367: 3362: 3359:(2): 117–21. 3358: 3354: 3346: 3338: 3334: 3330: 3326: 3321: 3316: 3312: 3308: 3304: 3297: 3280: 3278: 3273: 3267: 3265: 3263: 3261: 3252: 3248: 3243: 3238: 3234: 3230: 3226: 3222: 3218: 3211: 3203: 3199: 3194: 3189: 3185: 3181: 3178:(6): 787–94. 3177: 3173: 3169: 3162: 3154: 3150: 3145: 3144:10044/1/41218 3140: 3136: 3132: 3129:(9): 808–22. 3128: 3124: 3117: 3109: 3105: 3100: 3095: 3091: 3087: 3083: 3079: 3075: 3068: 3060: 3056: 3051: 3046: 3042: 3038: 3034: 3030: 3026: 3019: 3017: 3008: 3006:9780822585817 3002: 2998: 2994: 2990: 2986: 2979: 2971: 2967: 2963: 2959: 2955: 2951: 2947: 2943: 2936: 2928: 2924: 2920: 2916: 2912: 2908: 2904: 2898: 2890: 2886: 2881: 2876: 2873:(11): 734–9. 2872: 2868: 2864: 2857: 2855: 2846: 2842: 2838: 2834: 2830: 2826: 2822: 2815: 2807: 2803: 2798: 2793: 2789: 2785: 2781: 2777: 2773: 2766: 2758: 2754: 2750: 2746: 2742: 2738: 2731: 2715: 2711: 2710: 2705: 2699: 2691: 2687: 2683: 2679: 2675: 2671: 2667: 2663: 2656: 2654: 2645: 2641: 2637: 2633: 2632: 2627: 2620: 2612: 2608: 2603: 2598: 2594: 2590: 2586: 2579: 2571: 2567: 2563: 2559: 2556:(2): 415–29. 2555: 2551: 2544: 2542: 2533: 2529: 2525: 2521: 2517: 2513: 2508: 2503: 2499: 2495: 2491: 2487: 2480: 2464: 2460: 2459: 2454: 2448: 2440: 2436: 2432: 2428: 2424: 2420: 2413: 2411: 2402: 2398: 2393: 2388: 2384: 2382:9780124058804 2378: 2374: 2370: 2366: 2362: 2355: 2347: 2341: 2337: 2330: 2328: 2319: 2315: 2310: 2305: 2301: 2297: 2293: 2289: 2285: 2278: 2276: 2267: 2263: 2259: 2255: 2251: 2247: 2244:(2): 701–13. 2243: 2239: 2232: 2224: 2220: 2216: 2212: 2208: 2204: 2197: 2189: 2185: 2180: 2175: 2171: 2167: 2164:(6): 110=19. 2163: 2159: 2155: 2148: 2140: 2136: 2132: 2128: 2124: 2120: 2117:(6): 742–53. 2116: 2112: 2105: 2103: 2101: 2099: 2097: 2095: 2093: 2091: 2089: 2080: 2076: 2071: 2066: 2061: 2056: 2052: 2048: 2044: 2037: 2035: 2033: 2031: 2029: 2020: 2014: 2012: 2010: 2008: 2006: 2004: 2002: 2000: 1998: 1996: 1994: 1992: 1990: 1988: 1986: 1969: 1965: 1961: 1955: 1953: 1951: 1942: 1938: 1933: 1928: 1924: 1920: 1916: 1912: 1908: 1901: 1893: 1889: 1884: 1879: 1875: 1871: 1867: 1863: 1857: 1849: 1845: 1841: 1837: 1833: 1829: 1825: 1821: 1817: 1810: 1808: 1799: 1795: 1790: 1785: 1781: 1777: 1773: 1766: 1764: 1754: 1749: 1745: 1741: 1737: 1730: 1726: 1716: 1713: 1711: 1708: 1706: 1703: 1701: 1698: 1696: 1693: 1692: 1686: 1682: 1679: 1674: 1665: 1662: 1658: 1649: 1647: 1642: 1638: 1633: 1629: 1620: 1617: 1613: 1607: 1602: 1600: 1594: 1592: 1586: 1584: 1580: 1576: 1575:naive B cells 1572: 1568: 1566: 1562: 1558: 1552: 1550: 1546: 1542: 1538: 1534: 1530: 1526: 1522: 1518: 1514: 1510: 1506: 1505:spike protein 1502: 1498: 1494: 1489: 1487: 1483: 1482:mRNA vaccines 1479: 1478:AIDS epidemic 1475: 1466: 1464: 1460: 1450: 1448: 1444: 1443:valproic acid 1440: 1436: 1431: 1421: 1419: 1413: 1411: 1406: 1404: 1403:HIV infection 1400: 1396: 1392: 1387: 1384: 1383:gene knockout 1380: 1375: 1371: 1367: 1357: 1348: 1346: 1342: 1338: 1334: 1330: 1326: 1322: 1317: 1312: 1310: 1306: 1302: 1298: 1297: 1291: 1287: 1283: 1279: 1269: 1267: 1263: 1258: 1256: 1252: 1248: 1247:sperm washing 1244: 1238: 1228: 1226: 1221: 1216: 1210: 1200: 1191: 1189: 1185: 1184:triglycerides 1181: 1180:lipodystrophy 1177: 1173: 1164: 1162: 1158: 1148: 1144: 1142: 1138: 1134: 1130: 1126: 1122: 1121:mitochondrial 1118: 1108: 1100: 1098: 1094: 1093:Drug holidays 1085: 1083: 1078: 1073: 1070: 1060: 1058: 1054: 1045: 1043: 1042: 1037: 1034:for the U.S. 1033: 1029: 1023: 1018: 1016: 1011: 1007: 1006: 1001: 997: 992: 986: 969: 965: 962: 959: 958: 957: 949: 946: 942: 937: 927: 925: 921: 917: 913: 909: 908:liver disease 905: 904:heart disease 894: 890: 888: 881: 877: 867: 864: 859: 853: 850: 849: 848: 842: 841: 840: 837: 835: 830: 821: 819: 813: 811: 792: 788: 787: 786: 783: 781: 777: 772: 766: 762: 758: 754: 751: 747: 743: 739: 737: 733: 729: 725: 722: 719: 715: 712: 708: 704: 703: 702: 700: 695: 693: 689: 685: 681: 671: 669: 665: 651: 650: 649: 642: 639: 636: 635: 634: 631: 622: 620: 615: 613: 602: 598: 595: 591: 589: 583: 581: 577: 576: 571: 567: 566:control group 562: 558: 555: 551: 540: 536: 534: 530: 526: 521: 517: 513: 510: 506: 502: 496: 482: 479: 475: 471: 470:interleukin 2 460: 458: 454: 450: 442: 437: 433: 429: 427: 422: 416: 414: 410: 406: 402: 398: 395: 390: 387: 383: 379: 375: 371: 367: 363: 360: 356: 346: 344: 340: 336: 332: 328: 324: 320: 316: 312: 308: 303: 294: 292: 288: 284: 280: 275: 271: 267: 263: 254: 252: 248: 244: 240: 236: 232: 228: 224: 220: 211: 209: 205: 201: 200:emtricitabine 197: 193: 189: 185: 181: 176: 173: 169: 165: 156: 152: 150: 146: 142: 138: 134: 130: 126: 117: 114: 105: 96: 92: 90: 86: 82: 78: 73: 71: 67: 66:Anthony Fauci 63: 58: 56: 52: 48: 47:immune system 44: 40: 36: 32: 31:HIV infection 28: 24: 19: 11277:Hepatotoxins 11225: 11025:Cyanovirin-N 11015:Calanolide A 10691: 10685:2 generation 10659:1 generation 10646: 10617: 10596:Elvucitabine 10586:Apricitabine 10535: 10476:2 generation 10430:1 generation 10417: 10404:Fipravirimat 10318: 10313:Semzuvolimab 10302: 10293:Cenicriviroc 10277: 10265: 10253: 9934:Taiwan (ROC) 9924:Saudi Arabia 9774:South Africa 9607: 9593:Larry Kramer 9335:Epidemiology 9168: 9033: 9029: 8998: 8963: 8959: 8949: 8916: 8912: 8878: 8874: 8830: 8826: 8786: 8782: 8757:. Retrieved 8753:the original 8748: 8739: 8704: 8700: 8690: 8657: 8653: 8647: 8632: 8597: 8593: 8583: 8571:. Retrieved 8567: 8518: 8514: 8462: 8458: 8448: 8413: 8409: 8399: 8356: 8352: 8342: 8299: 8295: 8285: 8250: 8246: 8236: 8224:. Retrieved 8220: 8211: 8176: 8172: 8162: 8127: 8123: 8113: 8078: 8074: 8064: 8021: 8017: 8007: 7970: 7966: 7956: 7944:. Retrieved 7940:the original 7935: 7926: 7893: 7889: 7883: 7840: 7836: 7826: 7784:(2): e9390. 7781: 7777: 7767: 7732: 7728: 7718: 7707: 7697: 7662: 7658: 7648: 7613: 7609: 7599: 7572: 7568: 7558: 7546:. Retrieved 7540: 7530: 7518:. Retrieved 7512: 7502: 7490:. Retrieved 7486: 7476: 7464:. Retrieved 7457:the original 7444: 7432:. Retrieved 7428: 7418: 7406:. Retrieved 7402: 7392: 7383: 7348: 7344: 7334: 7302:(7): 692–8. 7299: 7295: 7285: 7273:. Retrieved 7269: 7259: 7226: 7198: 7178:16 September 7176:. Retrieved 7128: 7124: 7114: 7081: 7077: 7071: 7045:10.17226/771 7035: 7028: 7019: 7010: 6977: 6973: 6967: 6943:(3): 772–7. 6940: 6936: 6926: 6909: 6905: 6899: 6872: 6868: 6820: 6816: 6806: 6779: 6775: 6765: 6724: 6720: 6680: 6676: 6669: 6647:(5B): 9–15. 6644: 6640: 6634: 6604:(5): 422–8. 6601: 6597: 6591: 6556: 6546: 6514:(1): 18567. 6511: 6507: 6497: 6464: 6460: 6454: 6445: 6418: 6415:AIDS Reviews 6414: 6404: 6367: 6363: 6353: 6308: 6304: 6294: 6259: 6255: 6245: 6218: 6214: 6204: 6169: 6165: 6118:(1): 49–55. 6115: 6111: 6101: 6066: 6062: 6052: 6040:. Retrieved 6031: 5994: 5990: 5980: 5937: 5933: 5923: 5888: 5884: 5874: 5849: 5845: 5838: 5803: 5799: 5789: 5767:(1): 28–36. 5764: 5760: 5753: 5741:. Retrieved 5737:The Guardian 5735: 5721: 5700:. Retrieved 5691: 5684: 5650:(9): 830–9. 5647: 5643: 5630: 5618:. Retrieved 5612: 5605: 5568: 5564: 5516: 5512: 5505: 5496: 5489:. Retrieved 5452:. Retrieved 5434: 5410:(11): e475. 5407: 5403: 5393: 5381:. Retrieved 5367: 5340: 5336: 5326: 5293: 5289: 5247:(1): 106–7. 5244: 5240: 5234: 5222:. Retrieved 5218: 5209: 5197:. Retrieved 5193:the original 5188: 5178: 5143: 5139: 5129: 5117:. Retrieved 5113:the original 5108: 5099: 5087:. Retrieved 5077: 5065:. Retrieved 5061:the original 5051: 5016: 5012: 5002: 4967: 4963: 4915: 4911: 4863: 4859: 4849: 4822: 4818: 4808: 4776:(1): 17–25. 4773: 4769: 4759: 4724: 4720: 4710: 4678:(5): 741–7. 4675: 4671: 4661: 4649:. Retrieved 4596: 4592: 4552: 4548: 4538: 4501: 4497: 4487: 4452: 4448: 4438: 4413: 4409: 4402: 4390:. Retrieved 4341: 4337: 4331: 4314:10044/1/4267 4294: 4290: 4280: 4245: 4241: 4231: 4196: 4192: 4182: 4163: 4112: 4108: 4098: 4065: 4061: 4055: 4020: 4016: 4006: 3979: 3975: 3965: 3938: 3934: 3924: 3897: 3893: 3883: 3848: 3844: 3834: 3822:. Retrieved 3818: 3809: 3782: 3778: 3768: 3733: 3729: 3683: 3679: 3643: 3618: 3596: 3592: 3569: 3561:. Retrieved 3511: 3507: 3497: 3462: 3458: 3448: 3413: 3409: 3399: 3356: 3352: 3345: 3313:(4): 501–7. 3310: 3306: 3296: 3283:. Retrieved 3275: 3224: 3220: 3210: 3175: 3171: 3161: 3126: 3122: 3116: 3081: 3077: 3067: 3032: 3028: 2984: 2978: 2945: 2941: 2935: 2913:(7): 450–1. 2910: 2906: 2897: 2870: 2866: 2820: 2814: 2779: 2775: 2765: 2743:(8): 713–9. 2740: 2736: 2730: 2718:. Retrieved 2714:the original 2707: 2698: 2668:(2): 65–72. 2665: 2661: 2644:the original 2631:FDA Consumer 2629: 2619: 2595:(5): 962–8. 2592: 2588: 2578: 2553: 2549: 2489: 2485: 2479: 2467:. Retrieved 2463:the original 2456: 2447: 2425:(1): 59–74. 2422: 2418: 2364: 2354: 2335: 2294:(2): 111–8. 2291: 2287: 2241: 2237: 2231: 2206: 2202: 2196: 2161: 2157: 2147: 2114: 2110: 2050: 2047:BMC Medicine 2046: 1972:. Retrieved 1968:the original 1963: 1914: 1910: 1900: 1876:(4): 343–4. 1873: 1869: 1856: 1823: 1819: 1779: 1775: 1743: 1739: 1729: 1683: 1675: 1671: 1663: 1659: 1655: 1626: 1609: 1604: 1599:plasma cells 1595: 1587: 1569: 1553: 1535:, a type of 1509:retroviruses 1490: 1472: 1456: 1427: 1414: 1407: 1388: 1363: 1354: 1343:still being 1336: 1328: 1324: 1313: 1294: 1278:buyers clubs 1275: 1259: 1249:followed by 1240: 1212: 1197: 1188:heart attack 1170: 1154: 1145: 1114: 1106: 1091: 1074: 1066: 1055: 1051: 1039: 1025: 1020: 1017:as follows: 1014: 1003: 987: 983: 955: 933: 900: 897:Older adults 891: 883: 860: 857: 846: 838: 831: 827: 814: 806: 789:tenofovir + 784: 773: 770: 742:elvitegravir 718:dolutegravir 696: 677: 660: 647: 632: 628: 616: 608: 599: 596: 592: 584: 573: 546: 537: 533:cabotegravir 522: 518: 514: 497: 493: 466: 446: 430: 417: 391: 359:proofreading 352: 300: 291:cabotegravir 283:dolutegravir 279:elvitegravir 260: 217: 162: 153: 123: 110: 93: 74: 59: 42: 38: 22: 20: 18: 11226:recommended 11201:from market 11151:Lersivirine 11126:Capravirine 11065:Miltefosine 11050:Griffithsin 11045:Fosdevirine 10591:Censavudine 10221:(primarily 10142:New Zealand 10014:El Salvador 9919:Philippines 9889:North Korea 9842:China (PRC) 9807:Afghanistan 9497:Product Red 9398:AIDS orphan 9254:Nephropathy 9189:vaccination 8749:www.who.int 8573:30 November 8226:30 November 5726:Boseley S, 3982:(1): 12–4. 2995:. pp. 2238:Amino Acids 1565:coevolution 1515:gene. This 1418:CRISPR/Cas9 1389:After the " 1311:that year. 1225:raltegravir 1182:, elevated 1141:lipoatrophy 920:hepatitis C 916:hepatitis B 707:raltegravir 588:Chloe Orkin 529:rilpivirine 405:zalcitabine 287:bictegravir 274:raltegravir 270:integration 247:rilpivirine 133:enfuvirtide 11266:Categories 11156:Lodenosine 11136:Droxinavir 11121:Brecanavir 11116:Atevirdine 11080:Seliciclib 11075:Scytovirin 10989:Elipovimab 10934:TRIM5alpha 10611:Stampidine 10516:inhibitors 10500:TMC-310911 10399:BMS-955176 10297:Leronlimab 10289:Vicriviroc 9854:East Timor 9827:Bangladesh 9817:Azerbaijan 9739:Mozambique 9724:Madagascar 9457:Red ribbon 9299:Serostatus 9227:Conditions 9179:prevention 9169:management 9127:Lentivirus 8521:(2): 134. 7946:27 October 5378:HIV i-Base 5215:"Stribild" 4504:(1): 469. 4068:: 144–50. 3824:20 October 3285:16 October 1974:27 October 1721:References 1585:immunity. 1541:antibodies 1493:SARS-CoV-2 1447:vorinostat 1395:Virologist 1321:retronymic 1282:zidovudine 1161:Nevirapine 1077:phenotypic 1015:The Lancet 1005:The Lancet 936:depression 834:nevirapine 791:lamivudine 780:Cobicistat 746:cobicistat 732:HLA-B*5701 728:lamivudine 668:nevirapine 625:Guidelines 550:viral load 413:lamivudine 401:didanosine 397:zidovudine 331:atazanavir 319:amprenavir 315:nelfinavir 243:etravirine 235:nevirapine 196:lamivudine 188:zidovudine 172:nucleotide 168:nucleoside 137:Ibalizumab 113:retrovirus 11211:Phase III 11199:Withdrawn 11176:Telinavir 11171:Palinavir 11166:Mozenavir 11146:Emivirine 11141:Lasinavir 11111:Aplaviroc 11040:Foscarnet 11020:Ceragenin 10581:Amdoxovir 10394:Bevirimat 10371:BI 224436 10137:Australia 10091:Argentina 10051:Caribbean 10029:Nicaragua 10019:Guatemala 9929:Sri Lanka 9864:Indonesia 9647:Locations 9588:"Free Me" 9314:Pregnancy 9309:Nutrition 9164:diagnosis 8465:(1): 70. 7542:USA Today 7251:205649442 7174:. hiv.gov 5318:205038135 3361:CiteSeerX 2989:USA Today 2502:CiteSeerX 2111:AIDS Care 2053:(1): 94. 1459:cytokines 1333:computing 1309:Vancouver 1305:indinavir 1303:, namely 1284:(AZT), a 1253:(IUI) or 1176:ritonavir 1157:efavirenz 1129:steatosis 761:darunavir 757:ritonavir 664:stavudine 578:gave the 505:indinavir 503:, namely 457:adherence 426:synergies 409:stavudine 378:mutations 339:bevirimat 327:Darunavir 323:ritonavir 311:indinavir 307:lopinavir 266:integrase 239:efavirenz 204:tenofovir 175:analogues 129:Maraviroc 11256:Medicine 11161:Loviride 10106:Colombia 10024:Honduras 9939:Thailand 9914:Pakistan 9899:Malaysia 9837:Cambodia 9789:Zimbabwe 9769:Tanzania 9694:Ethiopia 9689:Eswatini 9674:Botswana 9563:Solidays 9462:Safe sex 9403:Religion 9347:Timeline 9269:Pruritus 9206:Children 9184:research 9159:HIV/AIDS 9137:subtypes 9052:15922953 8990:28291302 8941:13205040 8933:20650513 8895:17462800 8857:23591907 8805:26423814 8731:11348904 8682:12536749 8674:17848450 8624:32035643 8547:33562203 8515:Vaccines 8491:30326938 8440:27168247 8391:21998254 8334:23552890 8277:34242582 8203:28222903 8154:29326426 8105:21762802 8056:28302812 7999:16441880 7918:34104811 7910:23772631 7875:22837004 7818:20186346 7778:PLOS ONE 7759:24152233 7689:19543283 7640:25796552 7591:26670276 7575:: e268. 7375:24597865 7326:14905671 7318:19213682 7275:12 April 7243:24636252 7227:Virology 7155:24043435 7106:20023137 7063:25032454 7002:46624541 6994:20954881 6959:17107974 6891:23146867 6847:22980353 6839:11114835 6757:17032413 6749:23917901 6626:29497910 6618:22886031 6575:17525691 6538:24008177 6489:17275868 6437:24322381 6396:23749950 6345:22970105 6305:PLOS ONE 6286:11850253 6237:11526116 6196:16890836 6142:33402816 6134:10846593 6093:30411789 6042:13 April 6023:24968145 5972:22674331 5915:26850658 5885:Immunity 5866:19123868 5830:20467286 5728:Devlin H 5710:abstract 5676:27424812 5636:Cohen MS 5597:31056293 5541:51702998 5533:30025681 5448:Archived 5446:. 2019. 5426:29096785 5359:10357378 5310:22820792 5224:11 April 5199:11 April 5189:AIDSMeds 5170:24171517 5089:12 April 5067:11 April 5043:19381075 4994:29355886 4942:23549585 4890:20829678 4841:17420427 4792:23221765 4751:24556869 4702:12599047 4651:11 April 4625:15668871 4571:10432324 4530:26502899 4479:22716976 4430:19778270 4392:11 April 4366:24511465 4358:15464184 4323:18662132 4272:23323897 4223:22850510 4139:27943261 4090:23416260 4047:24429431 3998:23708678 3957:23798669 3916:15668873 3875:16299012 3801:25038359 3760:16090838 3752:17721103 3708:32501272 3700:17135583 3615:27404185 3538:22194547 3489:24152938 3440:21767103 3383:10708281 3337:21335467 3329:17301569 3251:18832878 3202:19193107 3153:26193126 3108:26192873 3059:19339714 2970:22747572 2962:10902643 2806:28542796 2757:17679131 2690:45429207 2682:17547827 2570:22728444 2532:13638059 2458:AIDSmeds 2439:19853627 2401:23885999 2318:23602471 2266:18521851 2258:22961335 2223:18691983 2188:30885900 2139:29881807 2131:19806490 2079:27334606 1941:24152939 1892:22820783 1862:Fauci AS 1848:58599661 1840:30629090 1816:Fauci AS 1798:10513653 1689:See also 1614:and the 1529:ribosome 1497:COVID-19 1351:Research 1337:computer 1276:Several 1137:myopathy 1127:, liver 1069:genotype 952:Concerns 945:Cochrane 912:dementia 852:abacavir 824:Children 752:> 70) 724:abacavir 674:Regimens 557:HPTN 052 509:David Ho 208:adefovir 192:abacavir 79:and the 11060:KP-1461 10606:Racivir 10376:MK-2048 10130:Oceania 10121:Uruguay 10096:Bolivia 10064:Jamaica 9982:Ukraine 9954:Vietnam 9822:Bahrain 9812:Armenia 9764:Senegal 9754:Nigeria 9744:Namibia 9719:Lesotho 9506:Culture 9487:HIV.gov 9330:History 9323:History 9066:HIVinfo 8981:5461871 8848:4448913 8759:7 March 8722:1120280 8615:7102617 8538:7915550 8482:6192334 8431:6034635 8382:3280215 8361:Bibcode 8353:Science 8325:3637846 8304:Bibcode 8268:8173590 8194:5388441 8145:5906799 8096:3139147 8047:5569908 8026:Bibcode 8018:Science 7990:1434768 7866:3704185 7845:Bibcode 7809:2826423 7786:Bibcode 7750:3954754 7680:2859814 7631:4403038 7548:5 March 7520:5 March 7492:23 July 7466:21 July 7434:21 July 7408:21 July 7366:4084652 7147:9287227 7098:8607591 6918:2109169 6798:9366579 6697:8512436 6661:9845490 6583:3113311 6529:3764307 6469:Bibcode 6428:4001077 6336:3433792 6313:Bibcode 6187:2913538 6084:6517236 6014:4072797 5963:3659421 5942:Bibcode 5934:Science 5906:6836297 5821:3018341 5781:7903975 5667:5049503 5620:2 April 5588:6584382 5454:2 April 5383:2 April 5269:9648307 5249:Bibcode 5161:3913536 5085:. Avert 5034:2704206 4985:6491182 4933:3684249 4881:3136814 4800:7554571 4742:4004637 4693:3384731 4521:4623925 4470:3443859 4263:4131004 4214:3457391 4130:5450880 4070:Bibcode 4038:3988426 3866:1309643 3563:2 April 3516:Bibcode 3508:Science 3480:3880570 3431:3200068 3391:3035239 3242:2715844 3193:2720023 3099:4569751 3050:2854555 2927:7616996 2889:9287228 2837:7614897 2797:5458151 2720:9 April 2709:Aidsmap 2611:8896496 2524:8599114 2494:Bibcode 2486:Science 2469:27 June 2392:7569752 2309:4097814 2179:6535568 2070:4916540 1932:4058441 1695:AV-HALT 1579:humoral 1549:antigen 1533:B cells 1381:-based 1272:History 697:The US 575:Science 559:, 1763 362:enzymes 343:vivecon 145:tropism 11242:Portal 11194:WHO-EM 11010:BIT225 11005:Abzyme 10936:(gene) 10623:NtRTIs 10518:(RTIs) 10111:Guyana 10101:Brazil 10009:Mexico 10004:Canada 9977:Russia 9964:Europe 9949:Turkey 9884:Jordan 9847:Yunnan 9832:Bhutan 9784:Zambia 9779:Uganda 9759:Rwanda 9729:Malawi 9704:Guinea 9664:Angola 9656:Africa 9603:ACT UP 9391:Social 9109:topics 9050: 8988: 8978: 8939: 8931: 8913:Lancet 8893: 8855: 8845: 8803: 8729: 8719: 8680: 8672: 8622: 8612: 8545: 8535: 8489: 8479: 8438: 8428: 8389: 8379: 8332: 8322: 8296:Nature 8275: 8265: 8201: 8191: 8152: 8142: 8103: 8093: 8054: 8044: 7997: 7987: 7916: 7908: 7873: 7863: 7837:Nature 7816: 7806: 7757: 7747: 7687: 7677: 7638: 7628: 7589: 7373: 7363: 7324: 7316: 7249: 7241: 7153: 7145: 7104: 7096: 7061: 7051: 7000: 6992: 6957: 6916: 6889: 6845: 6837: 6796: 6755: 6747: 6741:672271 6739: 6695: 6659: 6624: 6616: 6581: 6573: 6536: 6526: 6487: 6435: 6425: 6394: 6343: 6333: 6284: 6277:127499 6274: 6235: 6194: 6184: 6166:Lancet 6140: 6132: 6091: 6081: 6021: 6011: 5970: 5960: 5913: 5903: 5864: 5828: 5818: 5779: 5674: 5664: 5595: 5585: 5565:Lancet 5539: 5531: 5424: 5357: 5316: 5308: 5267: 5219:GoodRx 5168: 5158: 5119:2 June 5041: 5031: 4992: 4982: 4940: 4930: 4888: 4878: 4839: 4798: 4790: 4749: 4739: 4700: 4690: 4623: 4569: 4528: 4518: 4477: 4467: 4428: 4364: 4356: 4338:Lancet 4321: 4270: 4260: 4221: 4211: 4170: 4137: 4127: 4088: 4045: 4035: 3996: 3955: 3914: 3873: 3863: 3799: 3758: 3750: 3706: 3698: 3651: 3613: 3536: 3487: 3477: 3459:Lancet 3438: 3428: 3389: 3381: 3363: 3335: 3327: 3249: 3239: 3200: 3190: 3151: 3106: 3096: 3057: 3047: 3003: 2997:90–101 2968: 2960: 2942:Lancet 2925: 2887: 2845:754662 2843: 2835: 2804: 2794: 2755: 2688: 2680: 2609: 2568: 2530: 2522: 2504: 2437: 2399: 2389: 2379: 2342: 2316: 2306: 2264: 2256: 2221: 2186: 2176: 2137: 2129: 2077: 2067: 1939: 1929: 1911:Lancet 1890: 1846: 1838: 1796: 1632:models 1503:has a 1430:latent 1151:NNRTIs 922:, and 759:, and 736:allele 411:, and 289:, and 10998:Other 10981:BNAbs 10541:NRTIs 10320:gp120 10059:Haiti 9909:Nepal 9879:Japan 9859:India 9749:Niger 9714:Kenya 9699:Ghana 9684:Egypt 9669:Benin 9007:(PDF) 8937:S2CID 8827:Drugs 8678:S2CID 7973:: 8. 7914:S2CID 7460:(PDF) 7453:(PDF) 7322:S2CID 7247:S2CID 7223:(PDF) 7151:S2CID 7102:S2CID 6998:S2CID 6843:S2CID 6753:S2CID 6737:JSTOR 6622:S2CID 6579:S2CID 6138:S2CID 5743:3 May 5702:3 May 5696:(PDF) 5537:S2CID 5491:3 May 5314:S2CID 4796:S2CID 4645:(PDF) 4386:(PDF) 4362:S2CID 3756:S2CID 3704:S2CID 3676:(PDF) 3387:S2CID 3333:S2CID 3279:(EMA) 2966:S2CID 2903:Ho DD 2841:S2CID 2821:Drugs 2686:S2CID 2528:S2CID 2262:S2CID 2135:S2CID 1844:S2CID 1507:. In 1491:Like 1117:NRTIs 1111:NRTIs 734:gene 692:INSTI 688:NNRTI 680:NRTIs 441:NIAID 382:virus 368:into 251:HIV-2 149:CXCR4 43:HAART 11223:DHHS 10279:CCR5 10267:gp41 10116:Peru 9894:Laos 9874:Iraq 9869:Iran 9799:Asia 9734:Mali 9637:Ayds 9194:PrEP 9107:AIDS 9048:PMID 8986:PMID 8964:2017 8929:PMID 8891:PMID 8853:PMID 8801:PMID 8761:2019 8727:PMID 8670:PMID 8620:PMID 8575:2021 8543:PMID 8487:PMID 8436:PMID 8387:PMID 8330:PMID 8273:PMID 8228:2021 8199:PMID 8173:Cell 8150:PMID 8101:PMID 8052:PMID 7995:PMID 7948:2015 7906:PMID 7871:PMID 7814:PMID 7755:PMID 7685:PMID 7636:PMID 7587:PMID 7550:2019 7522:2019 7494:2016 7468:2016 7436:2016 7410:2016 7371:PMID 7314:PMID 7277:2014 7239:PMID 7180:2024 7143:PMID 7094:PMID 7059:PMID 7049:ISBN 6990:PMID 6955:PMID 6914:PMID 6887:PMID 6835:PMID 6794:PMID 6745:PMID 6693:PMID 6657:PMID 6614:PMID 6571:PMID 6534:PMID 6485:PMID 6433:PMID 6392:PMID 6341:PMID 6282:PMID 6233:PMID 6192:PMID 6130:PMID 6089:PMID 6044:2014 6019:PMID 5968:PMID 5911:PMID 5862:PMID 5826:PMID 5800:AIDS 5777:PMID 5745:2019 5704:2019 5672:PMID 5622:2019 5593:PMID 5529:PMID 5493:2019 5456:2019 5422:PMID 5385:2019 5355:PMID 5337:AIDS 5306:PMID 5290:JAMA 5265:PMID 5226:2014 5201:2014 5166:PMID 5121:2019 5091:2014 5069:2014 5039:PMID 5013:AIDS 4990:PMID 4938:PMID 4912:JAMA 4886:PMID 4860:AIDS 4837:PMID 4788:PMID 4747:PMID 4721:AIDS 4698:PMID 4653:2014 4621:PMID 4567:PMID 4526:PMID 4475:PMID 4426:PMID 4394:2014 4354:PMID 4319:PMID 4268:PMID 4219:PMID 4168:ISBN 4135:PMID 4113:2016 4086:PMID 4043:PMID 3994:PMID 3953:PMID 3912:PMID 3871:PMID 3826:2023 3797:PMID 3779:JAMA 3748:PMID 3730:AIDS 3696:PMID 3649:ISBN 3611:PMID 3593:JAMA 3570:Note 3565:2019 3534:PMID 3485:PMID 3436:PMID 3379:PMID 3353:AIDS 3325:PMID 3307:AIDS 3287:2020 3247:PMID 3221:AIDS 3198:PMID 3149:PMID 3104:PMID 3055:PMID 3001:ISBN 2985:AIDS 2958:PMID 2923:PMID 2885:PMID 2833:PMID 2802:PMID 2780:2017 2753:PMID 2722:2014 2678:PMID 2607:PMID 2566:PMID 2520:PMID 2471:2012 2435:PMID 2397:PMID 2377:ISBN 2340:ISBN 2314:PMID 2254:PMID 2219:PMID 2184:PMID 2127:PMID 2075:PMID 1976:2015 1937:PMID 1888:PMID 1870:JAMA 1836:PMID 1820:JAMA 1794:PMID 1776:AIDS 1521:mRNA 1445:and 1374:CCR5 1327:and 1139:and 1115:The 1002:and 910:and 878:and 709:(an 699:DHHS 523:The 372:via 353:The 341:and 329:and 321:and 245:and 237:and 206:and 170:and 166:are 141:CCR5 135:and 62:AIDS 21:The 10304:CD4 10223:J05 10219:HIV 9122:HIV 9115:HIV 9103:HIV 9038:doi 8976:PMC 8968:doi 8921:doi 8917:376 8883:doi 8843:PMC 8835:doi 8791:doi 8717:PMC 8709:doi 8705:322 8701:BMJ 8662:doi 8610:PMC 8602:doi 8533:PMC 8523:doi 8477:PMC 8467:doi 8426:PMC 8418:doi 8377:PMC 8369:doi 8357:334 8320:PMC 8312:doi 8300:496 8263:PMC 8255:doi 8189:PMC 8181:doi 8177:168 8140:PMC 8132:doi 8091:PMC 8083:doi 8079:410 8042:PMC 8034:doi 8022:355 7985:PMC 7975:doi 7898:doi 7894:254 7861:PMC 7853:doi 7841:487 7804:PMC 7794:doi 7745:PMC 7737:doi 7733:369 7675:PMC 7667:doi 7626:PMC 7618:doi 7577:doi 7403:CNN 7361:PMC 7353:doi 7349:370 7304:doi 7300:360 7231:doi 7133:doi 7129:337 7086:doi 7082:124 7041:doi 6982:doi 6945:doi 6877:doi 6825:doi 6784:doi 6780:337 6729:doi 6685:doi 6681:153 6649:doi 6645:102 6606:doi 6561:doi 6524:PMC 6516:doi 6477:doi 6465:220 6423:PMC 6382:hdl 6372:doi 6331:PMC 6321:doi 6272:PMC 6264:doi 6223:doi 6219:276 6182:PMC 6174:doi 6170:368 6120:doi 6079:PMC 6071:doi 6009:PMC 5999:doi 5958:PMC 5950:doi 5938:336 5901:PMC 5893:doi 5854:doi 5816:PMC 5808:doi 5769:doi 5765:169 5662:PMC 5652:doi 5648:375 5583:PMC 5573:doi 5569:393 5521:doi 5412:doi 5345:doi 5298:doi 5294:308 5257:doi 5245:279 5156:PMC 5148:doi 5144:369 5029:PMC 5021:doi 4980:PMC 4972:doi 4928:PMC 4920:doi 4916:309 4876:PMC 4868:doi 4827:doi 4823:167 4778:doi 4737:PMC 4729:doi 4688:PMC 4680:doi 4676:187 4611:hdl 4601:doi 4557:doi 4553:341 4516:PMC 4506:doi 4465:PMC 4457:doi 4453:366 4418:doi 4346:doi 4342:364 4309:hdl 4299:doi 4295:198 4258:PMC 4250:doi 4246:368 4209:PMC 4201:doi 4125:PMC 4117:doi 4078:doi 4033:PMC 4025:doi 3984:doi 3943:doi 3902:doi 3861:PMC 3853:doi 3849:331 3845:BMJ 3787:doi 3783:312 3738:doi 3688:doi 3684:355 3601:doi 3597:316 3524:doi 3512:334 3475:PMC 3467:doi 3463:382 3426:PMC 3418:doi 3414:365 3371:doi 3315:doi 3237:PMC 3229:doi 3188:PMC 3180:doi 3139:hdl 3131:doi 3127:373 3094:PMC 3086:doi 3082:373 3045:PMC 3037:doi 3033:360 2950:doi 2946:355 2915:doi 2911:333 2875:doi 2871:337 2825:doi 2792:PMC 2784:doi 2745:doi 2741:120 2670:doi 2597:doi 2593:174 2558:doi 2554:169 2512:doi 2490:271 2427:doi 2387:PMC 2369:doi 2304:PMC 2296:doi 2246:doi 2211:doi 2174:PMC 2166:doi 2119:doi 2065:PMC 2055:doi 1927:PMC 1919:doi 1915:382 1878:doi 1874:308 1828:doi 1824:321 1784:doi 1748:doi 1563:of 1513:Env 1501:HIV 1463:tat 1290:FDA 996:CDC 750:gfr 478:CD4 370:DNA 366:RNA 229:of 85:HIV 35:HIV 11268:: 11207:: 10311:, 10295:, 10291:, 10213:: 9046:. 9034:11 9032:. 9028:. 8984:. 8974:. 8962:. 8958:. 8935:. 8927:. 8915:. 8903:^ 8889:. 8879:65 8877:. 8865:^ 8851:. 8841:. 8831:73 8829:. 8825:. 8813:^ 8799:. 8785:. 8781:. 8769:^ 8747:. 8725:. 8715:. 8703:. 8699:. 8676:. 8668:. 8658:26 8656:. 8618:. 8608:. 8598:42 8596:. 8592:. 8566:. 8555:^ 8541:. 8531:. 8517:. 8513:. 8499:^ 8485:. 8475:. 8463:15 8461:. 8457:. 8434:. 8424:. 8414:34 8412:. 8408:. 8385:. 8375:. 8367:. 8355:. 8351:. 8328:. 8318:. 8310:. 8298:. 8294:. 8271:. 8261:. 8251:29 8249:. 8245:. 8219:. 8197:. 8187:. 8175:. 8171:. 8148:. 8138:. 8128:17 8126:. 8122:. 8099:. 8089:. 8077:. 8073:. 8050:. 8040:. 8032:. 8020:. 8016:. 7993:. 7983:. 7969:. 7965:. 7934:. 7912:. 7904:. 7892:. 7869:. 7859:. 7851:. 7839:. 7835:. 7812:. 7802:. 7792:. 7780:. 7776:. 7753:. 7743:. 7731:. 7727:. 7706:. 7683:. 7673:. 7663:15 7661:. 7657:. 7634:. 7624:. 7612:. 7608:. 7585:. 7571:. 7567:. 7539:. 7511:. 7485:. 7427:. 7401:. 7369:. 7359:. 7347:. 7343:. 7320:. 7312:. 7298:. 7294:. 7268:. 7245:. 7237:. 7225:. 7208:^ 7188:^ 7163:^ 7149:. 7141:. 7127:. 7123:. 7100:. 7092:. 7080:. 7057:. 7047:. 7039:. 7018:. 6996:. 6988:. 6976:. 6953:. 6941:22 6939:. 6935:. 6910:39 6908:. 6885:. 6873:19 6871:. 6867:. 6855:^ 6841:. 6833:. 6821:25 6819:. 6815:. 6792:. 6778:. 6774:. 6751:. 6743:. 6735:. 6725:34 6723:. 6719:. 6705:^ 6691:. 6679:. 6655:. 6643:. 6620:. 6612:. 6600:. 6577:. 6569:. 6555:. 6532:. 6522:. 6512:16 6510:. 6506:. 6483:. 6475:. 6463:. 6431:. 6419:15 6417:. 6413:. 6390:. 6380:. 6368:68 6366:. 6362:. 6339:. 6329:. 6319:. 6307:. 6303:. 6280:. 6270:. 6260:46 6258:. 6254:. 6231:. 6217:. 6213:. 6190:. 6180:. 6168:. 6164:. 6150:^ 6136:. 6128:. 6114:. 6110:. 6087:. 6077:. 6067:11 6065:. 6061:. 6017:. 6007:. 5995:10 5993:. 5989:. 5966:. 5956:. 5948:. 5936:. 5932:. 5909:. 5899:. 5889:44 5887:. 5883:. 5860:. 5850:48 5848:. 5824:. 5814:. 5804:24 5802:. 5798:. 5775:. 5763:. 5734:. 5670:. 5660:. 5646:. 5642:. 5591:. 5581:. 5567:. 5563:. 5549:^ 5535:. 5527:. 5515:. 5495:. 5484:. 5464:^ 5442:. 5420:. 5406:. 5376:. 5353:. 5341:13 5339:. 5335:. 5312:. 5304:. 5292:. 5277:^ 5263:. 5255:. 5243:. 5217:. 5187:. 5164:. 5154:. 5142:. 5138:. 5107:. 5037:. 5027:. 5017:23 5015:. 5011:. 4988:. 4978:. 4966:. 4962:. 4950:^ 4936:. 4926:. 4914:. 4910:. 4898:^ 4884:. 4874:. 4864:24 4862:. 4858:. 4835:. 4821:. 4817:. 4794:. 4786:. 4774:26 4772:. 4768:. 4745:. 4735:. 4725:28 4723:. 4719:. 4696:. 4686:. 4674:. 4670:. 4633:^ 4619:. 4609:. 4597:40 4595:. 4591:. 4579:^ 4565:. 4551:. 4547:. 4524:. 4514:. 4502:15 4500:. 4496:. 4473:. 4463:. 4451:. 4447:. 4424:. 4414:25 4412:. 4374:^ 4360:. 4352:. 4340:. 4317:. 4307:. 4293:. 4289:. 4266:. 4256:. 4244:. 4240:. 4217:. 4207:. 4197:56 4195:. 4191:. 4162:. 4147:^ 4133:. 4123:. 4111:. 4107:. 4084:. 4076:. 4066:16 4064:. 4041:. 4031:. 4021:58 4019:. 4015:. 3992:. 3980:13 3978:. 3974:. 3951:. 3939:68 3937:. 3933:. 3910:. 3898:40 3896:. 3892:. 3869:. 3859:. 3847:. 3843:. 3817:. 3795:. 3781:. 3777:. 3754:. 3746:. 3734:21 3732:. 3728:. 3716:^ 3702:. 3694:. 3682:. 3678:. 3663:^ 3626:^ 3617:. 3609:. 3595:. 3591:. 3577:^ 3546:^ 3532:. 3522:. 3510:. 3506:. 3483:. 3473:. 3461:. 3457:. 3434:. 3424:. 3412:. 3408:. 3385:. 3377:. 3369:. 3357:14 3355:. 3331:. 3323:. 3311:21 3309:. 3305:. 3274:. 3259:^ 3245:. 3235:. 3225:22 3223:. 3219:. 3196:. 3186:. 3176:48 3174:. 3170:. 3147:. 3137:. 3125:. 3102:. 3092:. 3080:. 3076:. 3053:. 3043:. 3031:. 3027:. 3015:^ 2999:. 2987:. 2964:. 2956:. 2944:. 2921:. 2909:. 2883:. 2869:. 2865:. 2853:^ 2839:. 2831:. 2800:. 2790:. 2778:. 2774:. 2751:. 2739:. 2706:. 2684:. 2676:. 2664:. 2652:^ 2638:, 2634:. 2628:. 2605:. 2591:. 2587:. 2564:. 2552:. 2540:^ 2526:. 2518:. 2510:. 2500:. 2488:. 2455:. 2433:. 2423:85 2421:. 2409:^ 2395:. 2385:. 2375:. 2363:. 2326:^ 2312:. 2302:. 2290:. 2286:. 2274:^ 2260:. 2252:. 2242:44 2240:. 2217:. 2207:30 2205:. 2182:. 2172:. 2162:63 2160:. 2156:. 2133:. 2125:. 2115:21 2113:. 2087:^ 2073:. 2063:. 2051:14 2049:. 2045:. 2027:^ 1984:^ 1962:. 1949:^ 1935:. 1925:. 1913:. 1909:. 1886:. 1872:. 1868:. 1842:. 1834:. 1822:. 1806:^ 1792:. 1780:13 1778:. 1774:. 1762:^ 1742:. 1738:. 1567:. 1499:, 1190:. 1135:, 1131:, 998:, 943:, 918:, 906:, 861:A 684:PI 451:. 407:, 403:, 399:, 325:. 317:, 313:, 309:, 293:. 285:, 281:, 249:. 210:. 198:, 194:, 190:, 131:, 11244:: 11221:° 10809:° 10803:° 10797:° 10786:° 10770:° 10754:° 10651:) 10647:( 10625:: 10621:/ 10543:: 10539:/ 10491:° 10485:° 10422:) 10418:( 10327:) 10323:( 10315:) 10307:( 10299:) 10282:( 10274:) 10270:( 10258:) 10254:( 10225:) 10203:e 10196:t 10189:v 9105:/ 9095:e 9088:t 9081:v 9054:. 9040:: 9009:. 8992:. 8970:: 8943:. 8923:: 8897:. 8885:: 8859:. 8837:: 8807:. 8793:: 8787:1 8763:. 8733:. 8711:: 8684:. 8664:: 8626:. 8604:: 8577:. 8549:. 8525:: 8519:9 8493:. 8469:: 8442:. 8420:: 8393:. 8371:: 8363:: 8336:. 8314:: 8306:: 8279:. 8257:: 8230:. 8205:. 8183:: 8156:. 8134:: 8107:. 8085:: 8058:. 8036:: 8028:: 8001:. 7977:: 7971:3 7950:. 7920:. 7900:: 7877:. 7855:: 7847:: 7820:. 7796:: 7788:: 7782:5 7761:. 7739:: 7712:. 7691:. 7669:: 7642:. 7620:: 7614:7 7593:. 7579:: 7573:4 7552:. 7524:. 7496:. 7470:. 7438:. 7412:. 7377:. 7355:: 7328:. 7306:: 7279:. 7253:. 7233:: 7202:. 7182:. 7157:. 7135:: 7108:. 7088:: 7065:. 7043:: 7004:. 6984:: 6978:8 6961:. 6947:: 6920:. 6893:. 6879:: 6849:. 6827:: 6800:. 6786:: 6759:. 6731:: 6699:. 6687:: 6663:. 6651:: 6628:. 6608:: 6602:7 6585:. 6563:: 6540:. 6518:: 6491:. 6479:: 6471:: 6439:. 6398:. 6384:: 6374:: 6347:. 6323:: 6315:: 6309:7 6288:. 6266:: 6239:. 6225:: 6198:. 6176:: 6144:. 6122:: 6116:5 6095:. 6073:: 6046:. 6025:. 6001:: 5974:. 5952:: 5944:: 5917:. 5895:: 5868:. 5856:: 5832:. 5810:: 5783:. 5771:: 5747:. 5716:) 5708:( 5706:. 5678:. 5654:: 5624:. 5599:. 5575:: 5543:. 5523:: 5517:5 5458:. 5428:. 5414:: 5408:4 5387:. 5361:. 5347:: 5320:. 5300:: 5271:. 5259:: 5251:: 5228:. 5203:. 5172:. 5150:: 5123:. 5093:. 5071:. 5045:. 5023:: 4996:. 4974:: 4968:1 4944:. 4922:: 4892:. 4870:: 4843:. 4829:: 4802:. 4780:: 4753:. 4731:: 4704:. 4682:: 4655:. 4627:. 4613:: 4603:: 4573:. 4559:: 4532:. 4508:: 4481:. 4459:: 4432:. 4420:: 4396:. 4368:. 4348:: 4325:. 4311:: 4301:: 4274:. 4252:: 4225:. 4203:: 4176:. 4141:. 4119:: 4092:. 4080:: 4072:: 4049:. 4027:: 4000:. 3986:: 3959:. 3945:: 3918:. 3904:: 3877:. 3855:: 3828:. 3803:. 3789:: 3762:. 3740:: 3710:. 3690:: 3657:. 3603:: 3567:. 3540:. 3526:: 3518:: 3491:. 3469:: 3442:. 3420:: 3393:. 3373:: 3339:. 3317:: 3289:. 3253:. 3231:: 3204:. 3182:: 3155:. 3141:: 3133:: 3110:. 3088:: 3061:. 3039:: 3009:. 2972:. 2952:: 2929:. 2917:: 2891:. 2877:: 2847:. 2827:: 2808:. 2786:: 2759:. 2747:: 2724:. 2692:. 2672:: 2666:4 2613:. 2599:: 2572:. 2560:: 2534:. 2514:: 2496:: 2473:. 2441:. 2429:: 2403:. 2371:: 2348:. 2320:. 2298:: 2292:3 2268:. 2248:: 2225:. 2213:: 2190:. 2168:: 2141:. 2121:: 2081:. 2057:: 1978:. 1943:. 1921:: 1894:. 1880:: 1850:. 1830:: 1800:. 1786:: 1756:. 1750:: 1744:5 767:) 726:/ 713:) 690:/ 686:/ 41:(

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

Knowledge

Management of HIV/AIDS

Index